

Francesco Soria

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1650106/publications.pdf>

Version: 2024-02-01

1,128
papers

47,809
citations

1368

108
h-index

4203

174
g-index

1136
all docs

1136
docs citations

1136
times ranked

21689
citing authors

#	ARTICLE	IF	CITATIONS
1	EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. European Urology, 2017, 71, 447-461.	0.9	1,594
2	EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013. European Urology, 2013, 64, 639-653.	0.9	1,053
3	Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer, 2009, 115, 1224-1233.	2.0	943
4	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta/T1 and T1/T2) 2016. European Urology, 2016, 69, 1071-1079.	0.9	936
5	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. European Urology, 2015, 68, 868-879.	0.9	804
6	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. European Urology, 2018, 73, 111-122.	0.9	627
7	Outcomes of Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: A Contemporary Series From the Bladder Cancer Research Consortium. Journal of Urology, 2006, 176, 2414-2422.	0.2	613
8	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and T1/T2) 2016. European Urology, 2016, 69, 1071-1079.	0.9	559
9	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. European Urology, 2021, 79, 62-79.	0.9	532
10	Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. European Urology, 2016, 69, 300-310.	0.9	460
11	Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. New England Journal of Medicine, 2021, 384, 2102-2114.	13.9	427
12	European Guidelines on Upper Tract Urothelial Carcinomas: 2013 Update. European Urology, 2013, 63, 1059-1071.	0.9	414
13	Prognostic Factors in Upper Urinary Tract Urothelial Carcinomas: A Comprehensive Review of the Current Literature. European Urology, 2012, 62, 100-114.	0.9	349
14	Discrepancy between Clinical and Pathologic Stage: Impact on Prognosis after Radical Cystectomy. European Urology, 2007, 51, 137-151.	0.9	307
15	Urothelial Carcinoma of the Bladder and the Upper Tract: Disparate Twins. Journal of Urology, 2013, 189, 1214-1221.	0.2	291
16	p53, p21, pRB, and p16 Expression Predict Clinical Outcome in Cystectomy With Bladder Cancer. Journal of Clinical Oncology, 2004, 22, 1014-1024.	0.8	290
17	The effect of age and gender on bladder cancer: a critical review of the literature. BJU International, 2010, 105, 300-308.	1.3	281
18	Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review. European Urology, 2014, 66, 120-137.	0.9	277

#	ARTICLE	IF	CITATIONS
19	Lymphovascular Invasion Predicts Clinical Outcomes in Patients With Node-Negative Upper Tract Urothelial Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 612-618.	0.8	260
20	Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). <i>World Journal of Urology</i> , 2017, 35, 379-387.	1.2	260
21	Comparison of Nomograms With Other Methods for Predicting Outcomes in Prostate Cancer: A Critical Analysis of the Literature. <i>Clinical Cancer Research</i> , 2008, 14, 4400-4407.	3.2	252
22	Cancer Control and Functional Outcomes of Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer: A Systematic Review of the Literature. <i>European Urology</i> , 2012, 61, 961-971.	0.9	238
23	Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2015, 67, 241-249.	0.9	235
24	Stage Specific Lymph Node Metastasis Mapping in Radical Cystectomy Specimens. <i>Journal of Urology</i> , 2004, 171, 1830-1834.	0.2	226
25	ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, Diagnosis, and Molecular Markers. <i>European Urology</i> , 2013, 63, 4-15.	0.9	225
26	Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysis. <i>Cancer Epidemiology</i> , 2013, 37, 219-225.	0.8	222
27	Preoperative Hydronephrosis, Ureteroscopic Biopsy Grade and Urinary Cytology Can Improve Prediction of Advanced Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2010, 184, 69-73.	0.2	221
28	Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy. <i>Clinical Cancer Research</i> , 2006, 12, 6663-6676.	3.2	219
29	A Systematic Review and Meta-analysis of Clinicopathologic Factors Linked to Intravesical Recurrence After Radical Nephroureterectomy to Treat Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2015, 67, 1122-1133.	0.9	218
30	Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel. <i>European Urology</i> , 2016, 70, 1052-1068.	0.9	215
31	Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. <i>European Urology</i> , 2015, 68, 238-253.	0.9	211
32	Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2018, 73, 925-933.	0.9	209
33	OPTIMAL COMBINATIONS OF SYSTEMATIC SEXTANT AND LATERALLY DIRECTED BIOPSIES FOR THE DETECTION OF PROSTATE CANCER. <i>Journal of Urology</i> , 2001, 165, 1554-1559.	0.2	208
34	Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. <i>European Urology</i> , 2017, 72, 801-813.	0.9	205
35	Preoperative Plasma Levels of Transforming Growth Factor Beta ₁ (TGF- β ₁) Strongly Predict Progression in Patients Undergoing Radical Prostatectomy. <i>Journal of Clinical Oncology</i> , 2001, 19, 2856-2864.	0.8	203
36	Impact of Distal Ureter Management on Oncologic Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2014, 65, 210-217.	0.9	201

#	ARTICLE	IF	CITATIONS
37	Adjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma: Results From the Upper Tract Urothelial Carcinoma Collaboration. <i>Journal of Urology</i> , 2009, 182, 900-906.	0.2	200
38	Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. <i>Lancet Oncology</i> , The, 2007, 8, 128-136.	5.1	198
39	Challenges of Cancer Biomarker Profiling. <i>European Urology</i> , 2007, 52, 1601-1609.	0.9	198
40	European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. <i>European Urology</i> , 2021, 79, 480-488.	0.9	198
41	Urinary cytology has a poor performance for predicting invasive or high-grade upper tract urothelial carcinoma. <i>BJU International</i> , 2011, 108, 701-705.	1.3	195
42	Impact of gender on bladder cancer incidence, staging, and prognosis. <i>World Journal of Urology</i> , 2011, 29, 457-463.	1.2	194
43	Hexyl Aminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-up of Patients with Non-muscle-invasive Bladder Cancer: A Critical Review of the Current Literature. <i>European Urology</i> , 2013, 64, 624-638.	0.9	193
44	Prognostic Factors and Risk Groups in T1G3 Non-muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 Patients. <i>European Urology</i> , 2015, 67, 74-82.	0.9	190
45	Predicting Clinical Outcomes After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2012, 61, 818-825.	0.9	188
46	Impact of Lymph Node Dissection on Cancer Specific Survival in Patients With Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy. <i>Journal of Urology</i> , 2009, 181, 2482-2489.	0.2	186
47	Soft Tissue Surgical Margin Status is a Powerful Predictor of Outcomes After Radical Cystectomy: A Multicenter Study of More Than 4,400 Patients. <i>Journal of Urology</i> , 2010, 183, 2165-2170.	0.2	186
48	Nomogram for Predicting Disease Recurrence After Radical Cystectomy for Transitional Cell Carcinoma of the Bladder. <i>Journal of Urology</i> , 2006, 176, 1354-1362.	0.2	185
49	Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. <i>Cancer</i> , 2008, 112, 315-325.	2.0	185
50	Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. <i>BJU International</i> , 2011, 107, 898-904.	1.3	184
51	Preoperative Multivariable Prognostic Model for Prediction of Nonorgan Confined Urothelial Carcinoma of the Upper Urinary Tract. <i>Journal of Urology</i> , 2010, 184, 453-458.	0.2	182
52	Urine Markers for Detection and Surveillance of Non-muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2011, 60, 484-492.	0.9	176
53	Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer: A Multi-institutional Collaboration. <i>European Urology</i> , 2011, 60, 205-210.	0.9	175
54	Bladder cancer in the elderly. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 653-667.	0.8	174

#	ARTICLE	IF	CITATIONS
55	Urine Detection of Survivin is a Sensitive Marker for the Noninvasive Diagnosis of Bladder Cancer. <i>Journal of Urology</i> , 2004, 171, 626-630.	0.2	169
56	Association of Pre- and Postoperative Plasma Levels of Transforming Growth Factor β 21 and Interleukin 6 and Its Soluble Receptor with Prostate Cancer Progression. <i>Clinical Cancer Research</i> , 2004, 10, 1992-1999.	3.2	168
57	The Impact of Tumor Multifocality on Outcomes in Patients Treated With Radical Nephroureterectomy. <i>European Urology</i> , 2012, 61, 245-253.	0.9	168
58	Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. <i>BJU International</i> , 2012, 109, 77-82.	1.3	164
59	Prognostic Role and HER2 Expression of Circulating Tumor Cells in Peripheral Blood of Patients Prior to Radical Cystectomy: A Prospective Study. <i>European Urology</i> , 2012, 61, 810-817.	0.9	163
60	Critical review of prostate cancer predictive tools. <i>Future Oncology</i> , 2009, 5, 1555-1584.	1.1	162
61	Comparison of Oncologic Outcomes for Open and Laparoscopic Nephroureterectomy: A Multi-Institutional Analysis of 1249 Cases. <i>European Urology</i> , 2009, 56, 1-9.	0.9	161
62	Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. <i>BJU International</i> , 2009, 103, 307-311.	1.3	160
63	Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort. <i>European Urology</i> , 2010, 57, 300-309.	0.9	159
64	The Effect of Tumor Location on Prognosis in Patients Treated with Radical Nephroureterectomy at Memorial Sloan-Kettering Cancer Center. <i>European Urology</i> , 2010, 58, 574-580.	0.9	159
65	Effect of Smoking on Outcomes of Urothelial Carcinoma: A Systematic Review of the Literature. <i>European Urology</i> , 2014, 65, 742-754.	0.9	159
66	Survivin expression is associated with features of biologically aggressive prostate carcinoma. <i>Cancer</i> , 2004, 100, 751-757.	2.0	158
67	Venous Thromboembolism After Major Cancer Surgery. <i>JAMA Surgery</i> , 2014, 149, 43.	2.2	158
68	Clinical Outcomes Following Radical Cystectomy for Primary Nontransitional Cell Carcinoma of the Bladder Compared to Transitional Cell Carcinoma of the Bladder. <i>Journal of Urology</i> , 2006, 175, 2048-2053.	0.2	157
69	Prediction of 90-day Mortality After Radical Cystectomy for Bladder Cancer in a Prospective European Multicenter Cohort. <i>European Urology</i> , 2014, 66, 156-163.	0.9	156
70	NOMOGRAMS INCLUDING NUCLEAR MATRIX PROTEIN 22 FOR PREDICTION OF DISEASE RECURRENCE AND PROGRESSION IN PATIENTS WITH Ta, T1 OR CIS TRANSITIONAL CELL CARCINOMA OF THE BLADDER. <i>Journal of Urology</i> , 2005, 173, 1518-1525.	0.2	155
71	Impact of Tumor Location on Prognosis for Patients with Upper Tract Urothelial Carcinoma Managed by Radical Nephroureterectomy. <i>European Urology</i> , 2010, 57, 1072-1079.	0.9	155
72	Advanced Age Is Associated with Poorer Bladder Cancer-Specific Survival in Patients Treated with Radical Cystectomy. <i>European Urology</i> , 2007, 51, 699-708.	0.9	154

#	ARTICLE	IF	CITATIONS
73	Tumour Necrosis Is an Indicator of Aggressive Biology in Patients with Urothelial Carcinoma of the Upper Urinary Tract. <i>European Urology</i> , 2010, 57, 575-581.	0.9	154
74	Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. <i>European Journal of Cancer</i> , 2013, 49, 1889-1897.	1.3	154
75	Death Certificates Are Valid for the Determination of Cause of Death in Patients With Upper and Lower Tract Urothelial Carcinoma. <i>European Urology</i> , 2012, 61, 854-855.	0.9	152
76	Prediction of Cancer Specific Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Development of an Optimized Postoperative Nomogram Using Decision Curve Analysis. <i>Journal of Urology</i> , 2013, 189, 1662-1669.	0.2	152
77	Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2011, 29, 481-486.	1.2	149
78	Precystectomy Nomogram for Prediction of Advanced Bladder Cancer Stage. <i>European Urology</i> , 2006, 50, 1254-1262.	0.9	147
79	Characteristics and clinical significance of histological variants of bladder cancer. <i>Nature Reviews Urology</i> , 2017, 14, 651-668.	1.9	147
80	Combination of Multiple Molecular Markers Can Improve Prognostication in Patients With Locally Advanced and Lymph Node Positive Bladder Cancer. <i>Journal of Urology</i> , 2010, 183, 68-75.	0.2	146
81	Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. <i>BJU International</i> , 2006, 97, 997-1001.	1.3	144
82	Ki-67 Is an Independent Predictor of Bladder Cancer Outcome in Patients Treated with Radical Cystectomy for Organ-Confined Disease. <i>Clinical Cancer Research</i> , 2006, 12, 7369-7373.	3.2	144
83	Multi-Institutional Validation of the Predictive Value of Ki-67 Labeling Index in Patients With Urinary Bladder Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 114-119.	3.0	144
84	A Critical Appraisal of the Value of Lymph Node Dissection at Nephroureterectomy for Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2010, 75, 118-124.	0.5	144
85	Tumor markers in prostate cancer I: Blood-based markers. <i>Acta Oncologica</i> , 2011, 50, 61-75.	0.8	144
86	Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. <i>Cancer</i> , 2007, 109, 1106-1113.	2.0	140
87	Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. <i>Nature Communications</i> , 2019, 10, 2977.	5.8	140
88	Lymphadenectomy at the Time of Nephroureterectomy for Upper Tract Urothelial Cancer. <i>European Urology</i> , 2011, 60, 776-783.	0.9	135
89	Comparison of stage migration patterns between Europe and the USA: an analysis of 11,350 men treated with radical prostatectomy for prostate cancer. <i>BJU International</i> , 2008, 101, 1513-1518.	1.3	134
90	Prediction of Intravesical Recurrence After Radical Nephroureterectomy: Development of a Clinical Decision-making Tool. <i>European Urology</i> , 2014, 65, 650-658.	0.9	134

#	ARTICLE	IF	CITATIONS
91	Predictive and Prognostic Models in Radical Prostatectomy Candidates: A Critical Analysis of the Literature. <i>European Urology</i> , 2010, 58, 687-700.	0.9	132
92	International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. <i>BJU International</i> , 2010, 105, 1402-1412.	1.3	132
93	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	0.9	132
94	Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. <i>Prostate</i> , 2007, 67, 614-622.	1.2	131
95	A Population Based Assessment of Perioperative Mortality After Cystectomy for Bladder Cancer. <i>Journal of Urology</i> , 2009, 182, 70-77.	0.2	131
96	Predictive Value of Cell Cycle Biomarkers in Nonmuscle Invasive Bladder Transitional Cell Carcinoma. <i>Journal of Urology</i> , 2007, 177, 481-487.	0.2	130
97	Clinicians are poor raters of life expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. <i>BJU International</i> , 2007, 100, 1254-1258.	1.3	129
98	Chronic Kidney Disease After Nephrectomy in Patients with Small Renal Masses: A Retrospective Observational Analysis. <i>European Urology</i> , 2012, 62, 696-703.	0.9	129
99	Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. <i>Modern Pathology</i> , 2007, 20, 445-459.	2.9	128
100	Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephroureterectomy. <i>BJU International</i> , 2013, 112, 453-461.	1.3	128
101	What Is the Significance of Variant Histology in Urothelial Carcinoma?. <i>European Urology Focus</i> , 2020, 6, 653-663.	1.6	126
102	Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time. <i>European Urology</i> , 2014, 66, 361-370.	0.9	125
103	Statistical consideration for clinical biomarker research in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 389-400.	0.8	119
104	Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. <i>Urology</i> , 2003, 61, 1140-1145.	0.5	116
105	Prognostic Impact of Preoperative Neutrophil-to-Lymphocyte Ratio in Localized Nonclear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2013, 190, 1999-2004.	0.2	116
106	A Multinational, Multi-institutional Study Comparing Positive Surgical Margin Rates Among 22 393 Open, Laparoscopic, and Robot-assisted Radical Prostatectomy Patients. <i>European Urology</i> , 2014, 66, 450-456.	0.9	116
107	Improved Detection of Clinically Significant, Curable Prostate Cancer With Systematic 12-Core Biopsy. <i>Journal of Urology</i> , 2004, 171, 1089-1092.	0.2	114
108	Lymphovascular Invasion is a Pathological Feature of Biologically Aggressive Disease in Patients Treated With Radical Prostatectomy. <i>Journal of Urology</i> , 2004, 171, 1122-1127.	0.2	114

#	ARTICLE	IF	CITATIONS
109	Impact of Histological Variants on Clinical Outcomes of Patients with Upper Urinary Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2012, 188, 398-404.	0.2	114
110	Association of Preoperative Plasma Levels of Vascular Endothelial Growth Factor and Soluble Vascular Cell Adhesion Molecule-1 With Lymph Node Status and Biochemical Progression After Radical Prostatectomy. <i>Journal of Clinical Oncology</i> , 2004, 22, 1655-1663.	0.8	113
111	PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact. <i>Clinical Cancer Research</i> , 2018, 24, 6300-6307.	3.2	112
112	Grading of Urothelial Carcinoma and The New "World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016". <i>European Urology Focus</i> , 2019, 5, 457-466.	1.6	112
113	The impact of retransurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin. <i>BJU International</i> , 2016, 118, 44-52.	1.3	110
114	E-CADHERIN IMMUNOSTAINING OF BLADDER TRANSITIONAL CELL CARCINOMA, CARCINOMA IN SITU AND LYMPH NODE METASTASES WITH LONG-TERM FOLLOWUP. <i>Journal of Urology</i> , 2001, 165, 1473-1479.	0.2	109
115	Can nomograms be superior to other prediction tools?. <i>BJU International</i> , 2009, 103, 492-497.	1.3	108
116	Location of the Primary Tumor is Not an Independent Predictor of Cancer Specific Mortality in Patients With Upper Urinary Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2009, 182, 2177-2181.	0.2	106
117	Impact of Smoking and Smoking Cessation on Oncologic Outcomes in Primary Non-muscle-invasive Bladder Cancer. <i>European Urology</i> , 2013, 63, 724-732.	0.9	105
118	The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2018, 73, 543-557.	0.9	105
119	Gender-specific Differences in Clinicopathologic Outcomes Following Radical Cystectomy: An International Multi-institutional Study of More Than 8000 Patients. <i>European Urology</i> , 2014, 66, 913-919.	0.9	103
120	Impact of Smoking and Smoking Cessation on Outcomes in Bladder Cancer Patients Treated with Radical Cystectomy. <i>European Urology</i> , 2013, 64, 456-464.	0.9	101
121	Variability in the Performance of Nuclear Matrix Protein 22 for the Detection of Bladder Cancer. <i>Journal of Urology</i> , 2006, 176, 919-926.	0.2	100
122	The Role of Radical Prostatectomy and Lymph Node Dissection in Lymph Node-Positive Prostate Cancer: A Systematic Review of the Literature. <i>European Urology</i> , 2014, 66, 191-199.	0.9	100
123	Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1063-1072.	3.3	100
124	First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. <i>European Urology Oncology</i> , 2021, 4, 755-765.	2.6	100
125	Evidence-Based Validation of the Predictive Value of the American Association for the Surgery of Trauma Kidney Injury Scale. <i>Journal of Trauma</i> , 2007, 62, 933-939.	2.3	98
126	Impact of Smoking on Oncologic Outcomes of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. <i>European Urology</i> , 2013, 63, 1082-1090.	0.9	98

#	ARTICLE	IF	CITATIONS
127	Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and meta-analysis. <i>BJU International</i> , 2017, 120, 313-319.	1.3	98
128	An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2018, 36, 1981-1995.	1.2	95
129	Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 441-448.	0.8	94
130	Prognostic factors for upper urinary tract urothelial carcinoma. <i>Nature Reviews Urology</i> , 2011, 8, 440-447.	1.9	94
131	Comparison of the prognostic value of pretreatment measurements of systemic inflammatory response in patients undergoing curative resection of clear cell renal cell carcinoma. <i>World Journal of Urology</i> , 2015, 33, 2045-2052.	1.2	94
132	Predictive Value of Combined Immunohistochemical Markers in Patients With pT1 Urothelial Carcinoma at Radical Cystectomy. <i>Journal of Urology</i> , 2009, 182, 78-84.	0.2	93
133	Prevalence and Trends in Kidney Stone Among Adults in the USA: Analyses of National Health and Nutrition Examination Survey 2007-2018 Data. <i>European Urology Focus</i> , 2021, 7, 1468-1475.	1.6	92
134	Association of Angiogenesis Related Markers With Bladder Cancer Outcomes and Other Molecular Markers. <i>Journal of Urology</i> , 2010, 183, 1744-1750.	0.2	91
135	Urine markers for detection and surveillance of bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 222-229.	0.8	91
136	Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature. <i>World Journal of Urology</i> , 2018, 36, 157-170.	1.2	91
137	Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. <i>Human Pathology</i> , 2006, 37, 1568-1576.	1.1	88
138	Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 252-258.	0.8	88
139	Nomograms for Bladder Cancer. <i>European Urology</i> , 2008, 54, 41-53.	0.9	87
140	Systematic Review and Meta-Analysis of Perioperative and Oncologic Outcomes of Laparoscopic Cryoablation Versus Laparoscopic Partial Nephrectomy for the Treatment of Small Renal Tumors. <i>Journal of Urology</i> , 2014, 191, 1209-1217.	0.2	87
141	Molecular markers in bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 31-40.	1.2	86
142	Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort. <i>BJU International</i> , 2011, 108, 406-412.	1.3	84
143	E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. <i>Urology</i> , 2001, 57, 60-65.	0.5	83
144	Malignancy rates and diagnostic performance of the Bosniak classification for the diagnosis of cystic renal lesions in computed tomography - a systematic review and meta-analysis. <i>European Radiology</i> , 2017, 27, 2239-2247.	2.3	83

#	ARTICLE	IF	CITATIONS
145	Preoperative plasma levels of transforming growth factor γ 1 strongly predict clinical outcome in patients with bladder carcinoma. <i>Cancer</i> , 2001, 92, 2985-2992.	2.0	82
146	Cyclooxygenase-2 is Highly Expressed in Carcinoma in Situ and T1 Transitional Cell Carcinoma of the Bladder. <i>Journal of Urology</i> , 2003, 169, 938-942.	0.2	82
147	Female Gender Is Associated With a Worse Survival After Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Competing Risk Analysis. <i>Urology</i> , 2014, 83, 863-868.	0.5	82
148	Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. <i>Journal of Urology</i> , 2017, 197, 1419-1426.	0.2	82
149	Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes. <i>European Urology</i> , 2019, 75, 649-658.	0.9	82
150	PREOPERATIVE PLASMA LEVELS OF INTERLEUKIN-6 AND ITS SOLUBLE RECEPTOR PREDICT DISEASE RECURRENCE AND SURVIVAL OF PATIENTS WITH BLADDER CANCER. <i>Journal of Urology</i> , 2002, 167, 1475-1481.	0.2	80
151	Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 904-908.	0.8	80
152	Smoking and Bladder Cancer: A Systematic Review of Risk and Outcomes. <i>European Urology Focus</i> , 2015, 1, 17-27.	1.6	80
153	Improved Prediction of Disease Relapse after Radical Prostatectomy through a Panel of Preoperative Blood-Based Biomarkers. <i>Clinical Cancer Research</i> , 2008, 14, 3785-3791.	3.2	79
154	The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. <i>Nature Reviews Urology</i> , 2016, 13, 471-479.	1.9	79
155	Prevalence and trends in urinary incontinence among women in the United States, 2005â€“2018. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 166.e1-166.e12.	0.7	79
156	Prognostic value of p53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. <i>Urology</i> , 2000, 56, 735-740.	0.5	78
157	Conditional Survival After Radical Nephroureterectomy for Upper Tract Carcinoma. <i>European Urology</i> , 2015, 67, 803-812.	0.9	78
158	Gender differences in incidence and outcomes of urothelial and kidney cancer. <i>Nature Reviews Urology</i> , 2015, 12, 585-592.	1.9	78
159	Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. <i>BJU International</i> , 2010, 106, 1216-1222.	1.3	77
160	Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients. <i>World Journal of Urology</i> , 2011, 29, 487-494.	1.2	77
161	Predictors of cancerâ€“specific mortality after disease recurrence following radical cystectomy. <i>BJU International</i> , 2013, 111, E30-6.	1.3	77
162	Concomitant Carcinoma In Situ Is a Feature of Aggressive Disease in Patients With Organ-Confined TCC at Radical Cystectomy. <i>European Urology</i> , 2007, 51, 152-160.	0.9	76

#	ARTICLE	IF	CITATIONS
163	Impact of Histologic Subtype on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus. <i>European Urology</i> , 2014, 66, 577-583.	0.9	76
164	Prospective Evaluation of the Clinical Usefulness of Reflex Fluorescence In Situ Hybridization Assay in Patients With Atypical Cytology for the Detection of Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2008, 179, 2164-2169.	0.2	75
165	High-Grade Ureteroscopic Biopsy Is Associated with Advanced Pathology of Upper-Tract Urothelial Carcinoma Tumors at Definitive Surgical Resection. <i>Journal of Endourology</i> , 2012, 26, 398-402.	1.1	75
166	Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. <i>World Journal of Urology</i> , 2017, 35, 337-353.	1.2	74
167	Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2019, 5, 224-241.	1.6	74
168	Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. <i>European Urology</i> , 2020, 78, 661-669.	0.9	74
169	Pilot study of radiofrequency interstitial tumor ablation (RITA) for the treatment of radio-recurrent prostate cancer. <i>Prostate</i> , 2005, 65, 260-267.	1.2	73
170	Highly predictive survival nomogram after upper urinary tract urothelial carcinoma. <i>Cancer</i> , 2010, 116, 3774-3784.	2.0	73
171	Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 716-723.	0.8	73
172	Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 389-399.	0.8	72
173	Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel. <i>European Urology Focus</i> , 2020, 6, 479-489.	1.6	72
174	Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2020, 38, 1165-1175.	1.2	72
175	Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer. <i>Urologic Clinics of North America</i> , 2016, 43, 47-62.	0.8	71
176	Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. <i>World Journal of Urology</i> , 2018, 36, 1703-1709.	1.2	71
177	Transcriptomic heterogeneity in multifocal prostate cancer. <i>JCI Insight</i> , 2018, 3, .	2.3	71
178	The Effect of Neoadjuvant Chemotherapy on Perioperative Outcomes in Patients Who Have Bladder Cancer Treated with Radical Cystectomy: A Population-based Study. <i>European Urology</i> , 2014, 66, 561-568.	0.9	70
179	Survivin as a Prognostic Marker for Urothelial Carcinoma of the Bladder: A Multicenter External Validation Study. <i>Clinical Cancer Research</i> , 2009, 15, 7012-7019.	3.2	69
180	p53 expression in patients with advanced urothelial cancer of the urinary bladder. <i>BJU International</i> , 2010, 105, 489-495.	1.3	69

#	ARTICLE	IF	CITATIONS
181	Clinical Nodal Staging Scores for Bladder Cancer: A Proposal for Preoperative Risk Assessment. <i>European Urology</i> , 2012, 61, 237-242.	0.9	69
182	BAP1 Immunohistochemistry Predicts Outcomes in a Multi-Institutional Cohort with Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 191, 603-610.	0.2	69
183	Molecular markers in bladder cancer. <i>Current Opinion in Urology</i> , 2008, 18, 1-8.	0.9	68
184	Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. <i>BJU International</i> , 2013, 111, 249-255.	1.3	67
185	Lynch Syndrome: A Primer for Urologists and Panel Recommendations. <i>Journal of Urology</i> , 2015, 194, 21-29.	0.2	66
186	Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 335-341.	0.8	66
187	Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer. <i>European Urology Oncology</i> , 2018, 1, 403-410.	2.6	66
188	Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature. <i>European Urology</i> , 2020, 78, 209-220.	0.9	66
189	Correlation of Cyclooxygenase-2 Expression With Molecular Markers, Pathological Features and Clinical Outcome of Transitional Cell Carcinoma of the Bladder. <i>Journal of Urology</i> , 2003, 170, 985-989.	0.2	65
190	Stage-specific impact of pelvic lymph node dissection on survival in patients with non-metastatic bladder cancer treated with radical cystectomy. <i>BJU International</i> , 2012, 109, 1147-1154.	1.3	64
191	Critical evaluation of urinary markers for bladder cancer detection and monitoring. <i>Reviews in Urology</i> , 2008, 10, 120-35.	0.9	64
192	Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer. <i>BJU International</i> , 2019, 123, 959-967.	1.3	63
193	Outcomes of Patients with Clinical T1 Grade 3 Urothelial Cell Bladder Carcinoma Treated with Radical Cystectomy. <i>Urology</i> , 2008, 71, 302-307.	0.5	62
194	Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 666-672.	0.8	62
195	Postoperative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localised and/or locally advanced upper tract urothelial carcinoma without metastasis. <i>BJU International</i> , 2014, 114, 733-740.	1.3	62
196	Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. <i>Urology</i> , 2003, 61, 1053-1058.	0.5	61
197	Adenocarcinoma Versus Urothelial Carcinoma of the Urinary Bladder: Comparison Between Pathologic Stage at Radical Cystectomy and Cancer-specific Mortality. <i>Urology</i> , 2010, 75, 376-381.	0.5	61
198	Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology's Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. <i>BJU International</i> , 2018, 121, 252-259.	1.3	61

#	ARTICLE	IF	CITATIONS
199	Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials. <i>European Urology</i> , 2021, 79, 44-53.	0.9	61
200	Comparative Outcomes of Pure Squamous Cell Carcinoma and Urothelial Carcinoma With Squamous Differentiation in Patients Treated With Radical Cystectomy. <i>Journal of Urology</i> , 2012, 187, 74-79.	0.2	60
201	Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. <i>European Urology</i> , 2018, 73, 436-444.	0.9	60
202	Predictive Value of the Differential Expression of the Urokinase Plasminogen Activation Axis in Radical Prostatectomy Patients. <i>European Urology</i> , 2009, 55, 1124-1134.	0.9	59
203	Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2017, 198, 1253-1262.	0.2	58
204	Predictive value of expression of transforming growth factor- β 1 and its receptors in transitional cell carcinoma of the urinary bladder. <i>Cancer</i> , 2001, 92, 1475-1483.	2.0	57
205	External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. <i>European Urology</i> , 2019, 75, 319-328.	0.9	57
206	The preoperative prognostic nutritional index is an independent predictor of survival in patients with renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 68.e1-68.e7.	0.8	56
207	Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?. <i>Cancer</i> , 2019, 125, 1449-1458.	2.0	56
208	Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. <i>Cancer Research</i> , 2003, 63, 4662-70.	0.4	56
209	New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. <i>BJU International</i> , 2008, 101, 675-683.	1.3	55
210	Comparative Analysis of Oncologic Outcomes of Partial Ureterectomy vs Radical Nephroureterectomy in Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2013, 81, 972-978.	0.5	55
211	Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. <i>BJU International</i> , 2013, 111, 1215-1221.	1.3	55
212	A randomized double-blind placebo controlled phase II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or chemopromotion?. <i>Prostate</i> , 2015, 75, 1177-1186.	1.2	55
213	Early Postoperative Radiotherapy is Associated with Worse Functional Outcomes in Patients with Prostate Cancer. <i>Journal of Urology</i> , 2017, 197, 669-675.	0.2	55
214	Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 445-452.	0.9	55
215	Soluble Fas: A promising novel urinary marker for the detection of recurrent superficial bladder cancer. <i>Cancer</i> , 2006, 106, 1701-1707.	2.0	54
216	Survivin Expression in Patients with Non-Muscle-Invasive Urothelial Cell Carcinoma of the Bladder. <i>Urology</i> , 2007, 70, 482-486.	0.5	54

#	ARTICLE	IF	CITATIONS
217	p53 Predictive Value for pT1-2 N0 Disease at Radical Cystectomy. <i>Journal of Urology</i> , 2009, 182, 907-913.	0.2	54
218	Impact of perioperative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder. <i>BJU International</i> , 2014, 113, 393-398.	1.3	54
219	⁶⁴ Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human Studies. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2016, 31, 277-286.	0.7	54
220	Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 483.e17-483.e24.	0.8	54
221	Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients. <i>World Journal of Urology</i> , 2018, 36, 1019-1029.	1.2	54
222	Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. <i>European Urology Oncology</i> , 2021, 4, 182-191.	2.6	54
223	Risk of Cancer-specific Mortality following Recurrence After Radical Nephroureterectomy. <i>Annals of Surgical Oncology</i> , 2012, 19, 4337-4344.	0.7	53
224	Differences in trends in the use of robot-assisted and open radical cystectomy and changes over time in perioperative outcomes among selected centres in North America and Europe: an international multicentre collaboration. <i>BJU International</i> , 2019, 124, 656-664.	1.3	53
225	Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2021, 80, 549-563.	0.9	53
226	Detection of Clinically Significant, Occult Prostate Cancer Metastases in Lymph Nodes Using a Splice Variant-Specific RT-PCR Assay for Human Glandular Kallikrein. <i>Journal of Clinical Oncology</i> , 2003, 21, 1223-1231.	0.8	52
227	Female with bladder cancer: what and why is there a difference?. <i>Translational Andrology and Urology</i> , 2016, 5, 668-682.	0.6	52
228	Tissue expression of transforming growth factor- β 1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. <i>Urology</i> , 2004, 63, 1191-1197.	0.5	51
229	Immunohistochemical biomarkers for bladder cancer prognosis. <i>International Journal of Urology</i> , 2011, 18, 616-629.	0.5	51
230	Select Screening in a Specific High-Risk Population of Patients Suggests a Stage Migration Toward Detection of Non-muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2011, 59, 1026-1031.	0.9	51
231	Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology. <i>Cancer</i> , 2011, 117, 2892-2897.	2.0	51
232	Biomolecular Predictors of Urothelial Cancer Behavior and Treatment Outcomes. <i>Current Urology Reports</i> , 2012, 13, 122-135.	1.0	51
233	Contemporary role of lymph node dissection at the time of radical nephroureterectomy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2017, 35, 535-548.	1.2	51
234	Association of Smoking Status With Recurrence, Metastasis, and Mortality Among Patients With Localized Prostate Cancer Undergoing Prostatectomy or Radiotherapy. <i>JAMA Oncology</i> , 2018, 4, 953.	3.4	51

#	ARTICLE	IF	CITATIONS
235	EXPRESSION OF SURVIVIN AND APOPTOTIC BIOMARKERS IN BENIGN PROSTATIC HYPERPLASIA. <i>Journal of Urology</i> , 2005, 174, 2046-2050.	0.2	50
236	Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. <i>European Urology</i> , 2015, 68, 949-956.	0.9	50
237	Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 430-436.	0.8	50
238	Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer. <i>Human Pathology</i> , 2014, 45, 674-682.	1.1	49
239	Impact of Preoperative Anemia on Oncologic Outcomes of Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. <i>Journal of Urology</i> , 2014, 191, 316-322.	0.2	49
240	Response assessment using [⁶⁸ Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2020, 80, 74-82.	1.2	49
241	Clinical Outcomes of Primary Bladder Carcinoma In Situ in a Contemporary Series. <i>Journal of Urology</i> , 2010, 184, 74-80.	0.2	48
242	Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy. <i>BJU International</i> , 2013, 111, 404-411.	1.3	48
243	Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey. <i>European Urology Focus</i> , 2019, 5, 681-688.	1.6	48
244	Recurrence mechanisms of non-muscle-invasive bladder cancer – a clinical perspective. <i>Nature Reviews Urology</i> , 2022, 19, 280-294.	1.9	48
245	Pathologic Nodal Staging Score for Bladder Cancer: A Decision Tool for Adjuvant Therapy After Radical Cystectomy. <i>European Urology</i> , 2013, 63, 371-378.	0.9	47
246	Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy. <i>Journal of Surgical Oncology</i> , 2017, 115, 455-461.	0.8	46
247	Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients. <i>European Urology Oncology</i> , 2018, 1, 91-100.	2.6	46
248	Management of bladder cancer in older patients: Position paper of a SIOG Task Force. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1043-1053.	0.5	46
249	The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2021, 79, 783-792.	0.9	46
250	Features and outcomes of patients with grade IV renal injury. <i>BJU International</i> , 2008, 102, 728-733.	1.3	45
251	Impact of Smoking on Outcomes of Patients with a History of Recurrent Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2012, 188, 2120-2128.	0.2	45
252	A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens. <i>BJU International</i> , 2019, 123, 11-21.	1.3	45

#	ARTICLE	IF	CITATIONS
253	Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1892-1900.	1.0	45
254	Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurrence and prognostic significance. <i>Oncotarget</i> , 2016, 7, 39293-39301.	0.8	45
255	Expression of Cyclooxygenase-2 in Normal Urothelium, and Superficial and Advanced Transitional Cell Carcinoma of Bladder. <i>Journal of Urology</i> , 2007, 177, 1163-1168.	0.2	44
256	Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study. <i>BJU International</i> , 2011, 108, E304-E309.	1.3	44
257	Subclassification of pT3 Urothelial Carcinoma of the Renal Pelvicalyceal System is Associated With Recurrence-Free and Cancer-Specific Survival: Proposal for a Revision of the Current TNM Classification. <i>European Urology</i> , 2012, 62, 224-231.	0.9	44
258	Survival after radical cystectomy of non-muscle-invasive squamous cell carcinoma vs urothelial carcinoma: a competing risks analysis. <i>BJU International</i> , 2012, 109, 564-569.	1.3	44
259	An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer. <i>Biomolecules</i> , 2016, 6, 37.	1.8	44
260	Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 265-273.	2.0	44
261	Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 468-475.	0.8	43
262	Risk Stratification of Organ Confined Bladder Cancer After Radical Cystectomy Using Cell Cycle Related Biomarkers. <i>Journal of Urology</i> , 2012, 187, 457-462.	0.2	43
263	Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 65.e19-65.e25.	0.8	43
264	Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery. <i>Translational Andrology and Urology</i> , 2016, 5, 735-744.	0.6	43
265	Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction. <i>Journal of Urology</i> , 2017, 197, 287-295.	0.2	43
266	Immunocytology Is a Strong Predictor of Bladder Cancer Presence in Patients With Painless Hematuria: A Multicentre Study. <i>European Urology</i> , 2012, 61, 185-192.	0.9	42
267	Robot-assisted versus laparoscopic nephroureterectomy for uppertract urothelial cancer: A population-based assessment of costs and perioperative outcomes. <i>Canadian Urological Association Journal</i> , 2014, 8, 695.	0.3	42
268	Prospective evaluation of diffusion-weighted MRI of the bladder as a biomarker for prediction of bladder cancer aggressiveness. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1166-1171.	0.8	42
269	Molecular markers for urothelial bladder cancer prognosis: Toward implementation in clinical practice. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1078-1087.	0.8	42
270	Genetic determinants for chemo- and radiotherapy resistance in bladder cancer. <i>Translational Andrology and Urology</i> , 2017, 6, 1081-1089.	0.6	42

#	ARTICLE	IF	CITATIONS
271	Risk Stratification for Bladder Tumor Recurrence, Stage and Grade by Urinary Nuclear Matrix Protein 22 and Cytology. <i>European Urology</i> , 2004, 45, 304-313.	0.9	41
272	Impact of smoking status and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy. <i>BJU International</i> , 2014, 114, 56-61.	1.3	41
273	Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy. <i>World Journal of Urology</i> , 2017, 35, 1541-1547.	1.2	41
274	A urinary microRNA (miR) signature for diagnosis of bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 531.e1-531.e8.	0.8	41
275	Contemporary National Assessment of Robot-Assisted Surgery Rates and Total Hospital Charges for Major Surgical Uro-Oncological Procedures in the United States. <i>Journal of Endourology</i> , 2019, 33, 438-447.	1.1	41
276	Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study. <i>European Urology Focus</i> , 2019, 5, 488-496.	1.6	41
277	A Systematic Review and Meta-Analysis of Variant Histology in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. <i>Journal of Urology</i> , 2020, 204, 1129-1140.	0.2	41
278	Characteristics of normal prostate vascular anatomy as displayed by power Doppler. <i>Prostate</i> , 2001, 46, 281-288.	1.2	40
279	Prediction of True Nodal Status in Patients with Pathological Lymph Node Negative Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy. <i>Journal of Urology</i> , 2013, 189, 468-473.	0.2	40
280	Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. <i>Prostate</i> , 2018, 78, 469-475.	1.2	40
281	A systematic review and meta-analysis of lymphovascular invasion in patients treated with radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 293-305.	0.8	40
282	Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis. <i>European Urology</i> , 2020, 77, 583-598.	0.9	40
283	Incidence and Survival Rates of Contemporary Patients with Invasive Upper Tract Urothelial Carcinoma. <i>European Urology Oncology</i> , 2021, 4, 792-801.	2.6	40
284	Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy. <i>Future Science OA</i> , 2021, 7, FSO709.	0.9	40
285	Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. <i>European Urology Oncology</i> , 2021, 4, 927-942.	2.6	40
286	The Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy: Validation and Meta-analysis. <i>European Urology Focus</i> , 2016, 2, 79-85.	1.6	39
287	Patient frailty predicts worse perioperative outcomes and higher cost after radical cystectomy. <i>Surgical Oncology</i> , 2020, 32, 8-13.	0.8	39
288	Development of a Highly Accurate Nomogram for Prediction of the Need for Exploration in Patients With Renal Trauma. <i>Journal of Trauma</i> , 2008, 64, 1451-1458.	2.3	38

#	ARTICLE	IF	CITATIONS
289	Robotic-assisted Radical Cystectomy With Extracorporeal Urinary Diversion for Urothelial Carcinoma of the Bladder: Analysis of Complications and Oncologic Outcomes in 175 Patients With a Median Follow-up of 3 Years. <i>Urology</i> , 2013, 82, 1323-1329.	0.5	38
290	Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy. <i>BJU International</i> , 2014, 113, 70-76.	1.3	38
291	Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 49.e7-49.e14.	0.8	38
292	Multi-institutional Validation of the Predictive Value of Ki-67 in Patients with High Grade Urothelial Carcinoma of the Upper Urinary Tract. <i>Journal of Urology</i> , 2015, 193, 1486-1493.	0.2	38
293	Risk of Fracture After Radical Cystectomy and Urinary Diversion for Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3291-3298.	0.8	37
294	Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. <i>World Journal of Urology</i> , 2017, 35, 121-130.	1.2	37
295	Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis. <i>BJU International</i> , 2022, 129, 423-433.	1.3	37
296	Impact of smoking on outcomes after intravesical bacillus Calmette-Guérin therapy for urothelial carcinoma not invading muscle of the bladder. <i>BJU International</i> , 2011, 108, 526-530.	1.3	36
297	Assessment of the Quality-of-life and Functional Outcomes in Patients Undergoing Cystectomy and Urinary Diversion for the Management of Radiation-induced Refractory Benign Disease. <i>Urology</i> , 2015, 85, 394-401.	0.5	36
298	Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era. <i>International Urology and Nephrology</i> , 2017, 49, 2143-2149.	0.6	36
299	Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 8.e17-8.e24.	0.8	36
300	Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. <i>European Urology</i> , 2018, 73, 512-518.	0.9	36
301	The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2021, 205, 60-67.	0.2	36
302	Efficacy of Preoperative Chemotherapy for High Risk Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2020, 203, 1101-1108.	0.2	36
303	C: IGF-I IGFBP-3 I. <i>Urology</i> , 2003, 61, 359-364.	0.5	35
304	Clinical Outcome of Primary Versus Secondary Bladder Carcinoma In Situ. <i>Journal of Urology</i> , 2010, 184, 464-469.	0.2	35
305	Prospective Analysis of Ki-67 as an Independent Predictor of Oncologic Outcomes in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2014, 191, 28-34.	0.2	35
306	Prospective External Validation of a Bladder Cancer Detection Model. <i>Journal of Urology</i> , 2014, 192, 1343-1348.	0.2	35

#	ARTICLE	IF	CITATIONS
307	Cardiovascular Mortality in Patients With Metastatic Prostate Cancer Exposed to Androgen Deprivation Therapy: A Population-Based Study. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e123-e130.	0.9	35
308	Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase II study. <i>World Journal of Urology</i> , 2016, 34, 189-195.	1.2	35
309	Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2017, 197, 580-589.	0.2	35
310	Surgical checklist impact on recurrence-free survival of patients with non-muscle-invasive bladder cancer undergoing transurethral resection of bladder tumour. <i>BJU International</i> , 2019, 123, 646-650.	1.3	35
311	Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. <i>BJU International</i> , 2008, 101, 1362-1367.	1.3	34
312	The impact of hospital volume, residency, and fellowship training on perioperative outcomes after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 29.e13-29.e20.	0.8	34
313	In-hospital length of stay after major surgical oncological procedures. <i>European Journal of Surgical Oncology</i> , 2018, 44, 969-974.	0.5	34
314	Current Disease Management of Primary Urethral Carcinoma. <i>European Urology Focus</i> , 2019, 5, 722-734.	1.6	34
315	Quality Indicators for Bladder Cancer Services: A Collaborative Review. <i>European Urology</i> , 2020, 78, 43-59.	0.9	34
316	Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. <i>Reviews in Urology</i> , 2004, 6, 58-72.	0.9	34
317	Screening for prostate cancer: an update. <i>Canadian Journal of Urology</i> , 2008, 15, 4363-74.	0.0	34
318	Prospective two-arm study of the testicular function in patients with COVID-19. <i>Andrology</i> , 2022, 10, 1047-1056.	1.9	34
319	Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy. <i>World Journal of Urology</i> , 2012, 30, 753-759.	1.2	33
320	Smoking Reduces the Efficacy of Intravesical Bacillus Calmette-Guérin Immunotherapy in Non-muscle-invasive Bladder Cancer. <i>European Urology</i> , 2012, 62, 1204-1206.	0.9	33
321	Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 230-242.	0.8	33
322	Association of human telomerase reverse transcriptase gene polymorphisms, serum levels, and telomere length with renal cell carcinoma risk and pathology. <i>Molecular Carcinogenesis</i> , 2016, 55, 1458-1466.	1.3	33
323	HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). <i>World Journal of Urology</i> , 2017, 35, 251-259.	1.2	33
324	Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment. <i>Prostate</i> , 2017, 77, 686-693.	1.2	33

#	ARTICLE	IF	CITATIONS
325	Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e267-e273.	0.9	33
326	Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis. <i>Bladder Cancer</i> , 2018, 4, 91-112.	0.2	33
327	Comparison of perioperative complications and health-related quality of life between robot-assisted and open radical cystectomy: A systematic review and meta-analysis. <i>International Journal of Urology</i> , 2019, 26, 760-774.	0.5	33
328	Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. <i>European Urology Focus</i> , 2020, 6, 1233-1239.	1.6	33
329	Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. <i>Journal of Urology</i> , 2002, 167, 1475-81.	0.2	33
330	Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder. <i>World Journal of Urology</i> , 2018, 36, 231-240.	1.2	32
331	First North American validation and head-to-head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy. <i>BJU International</i> , 2018, 121, 592-599.	1.3	32
332	Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy. <i>BJU International</i> , 2019, 124, 738-745.	1.3	32
333	Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 309-315.	2.0	32
334	Prognostic value of preoperative blood-based biomarkers in upper tract urothelial carcinoma treated with nephroureterectomy: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 315-333.	0.8	32
335	The Impact of COVID-19 Outbreak on Uro-oncological Practice Across Europe: Which Burden of Activity Are We Facing Ahead?. <i>European Urology</i> , 2020, 78, 124-126.	0.9	32
336	Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. <i>European Urology</i> , 2022, 82, 341-351.	0.9	32
337	Review: Use of nomograms for predictions of outcome in patients with advanced bladder cancer. <i>Therapeutic Advances in Urology</i> , 2009, 1, 13-26.	0.9	31
338	Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes. <i>BJU International</i> , 2013, 112, 623-637.	1.3	31
339	Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 433-440.	0.8	31
340	Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: Results of a current series and a review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 54.e19-54.e26.	0.8	31
341	The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes. <i>European Urology Oncology</i> , 2019, 2, 541-548.	2.6	31
342	Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1037-1054.	1.0	31

#	ARTICLE	IF	CITATIONS
343	Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. <i>European Urology Focus</i> , 2021, 7, 124-131.	1.6	31
344	Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. <i>Journal of Urology</i> , 2022, 207, 16-24.	0.2	31
345	Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial. <i>BJU International</i> , 2012, 109, 685-690.	1.3	30
346	Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib. <i>Cancer Biology and Therapy</i> , 2014, 15, 1239-1247.	1.5	30
347	Is there any evidence of a "July effect" in patients undergoing major cancer surgery?. <i>Canadian Journal of Surgery</i> , 2014, 57, 82-88.	0.5	30
348	Is continent cutaneous urinary diversion a suitable alternative to orthotopic bladder substitute and ileal conduit after cystectomy?. <i>BJU International</i> , 2015, 116, 805-814.	1.3	30
349	Oncologic Outcomes of Kidney Sparing Surgery versus Radical Nephroureterectomy for the Elective Treatment of Clinically Organ Confined Upper Tract Urothelial Carcinoma of the Distal Ureter. <i>Journal of Urology</i> , 2016, 195, 1354-1361.	0.2	30
350	Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 264-271.	0.8	30
351	The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pT ₂ non-metastatic renal cell carcinoma treated with radical nephrectomy. <i>BJU International</i> , 2018, 121, 383-392.	1.3	30
352	Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2169-2177.	3.3	30
353	Performance of [68Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 1-10.	2.0	30
354	Prognostic Value of Variant Histology in Upper Tract Urothelial Carcinoma Treated with Nephroureterectomy: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2020, 203, 1075-1084.	0.2	30
355	Urinary Levels of Soluble E-Cadherin in the Detection of Transitional Cell Carcinoma of the Urinary Bladder. <i>European Urology</i> , 2005, 48, 69-76.	0.9	29
356	Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. <i>Urology</i> , 2006, 68, 538-542.	0.5	29
357	Prospective Comparison of Molecular Signatures in Urothelial Cancer of the Bladder and the Upper Urinary Tract "Is There Evidence for Discordant Biology?". <i>Journal of Urology</i> , 2014, 191, 926-931.	0.2	29
358	Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer. <i>European Urology</i> , 2014, 66, 1125-1132.	0.9	29
359	Carbonic Anhydrase IX as a Diagnostic Urinary Marker for Urothelial Bladder Cancer. <i>European Urology</i> , 2015, 68, 552-554.	0.9	29
360	The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. <i>BJU International</i> , 2015, 116, 72-78.	1.3	29

#	ARTICLE	IF	CITATIONS
361	Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder: development of a tool for clinical decision-making. <i>BJU International</i> , 2016, 117, 272-279.	1.3	29
362	Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. <i>World Journal of Urology</i> , 2017, 35, 1401-1407.	1.2	29
363	Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Primary Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e755-e764.	0.9	29
364	Diagnostic Value of 18F-fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for Lymph Node Staging in Patients with Upper Tract Urothelial Carcinoma. <i>European Urology Oncology</i> , 2020, 3, 73-79.	2.6	29
365	The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 3.e17-3.e27.	0.8	29
366	Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 399-408.	1.6	29
367	Role of Radiomics in the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 728-738.	1.6	29
368	Quantitative Apparent Diffusion Coefficient Measurements Obtained by 3-Tesla MRI Are Correlated with Biomarkers of Bladder Cancer Proliferative Activity. <i>PLoS ONE</i> , 2014, 9, e106866.	1.1	29
369	The Addition of Urinary Urokinase-Type Plasminogen Activator to Urinary Nuclear Matrix Protein 22 and Cytology Improves the Detection of Bladder Cancer. <i>Journal of Urology</i> , 2003, 170, 2244-2247.	0.2	28
370	Early Postoperative Plasma Transforming Growth Factor- β 1 is a Strong Predictor of Biochemical Progression After Radical Prostatectomy. <i>Journal of Urology</i> , 2008, 179, 1593-1597.	0.2	28
371	Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis. <i>Journal of Urology</i> , 2015, 194, 304-309.	0.2	28
372	Optimizing outcome reporting after radical cystectomy for organ-confined urothelial carcinoma of the bladder using oncological trifecta and pentapecta. <i>World Journal of Urology</i> , 2015, 33, 1945-1950.	1.2	28
373	Marital status and gender affect stage, tumor grade, treatment type and cancer specific mortality in T1-2 NO M0 renal cell carcinoma. <i>World Journal of Urology</i> , 2017, 35, 1899-1905.	1.2	28
374	Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making tool. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 239.e1-239.e7.	0.8	28
375	Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies. <i>Journal of Urology</i> , 2018, 199, 1149-1157.	0.2	28
376	Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 637-646.	0.8	28
377	Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy. <i>European Urology Oncology</i> , 2021, 4, 170-179.	2.6	28
378	Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 139-148.	2.0	28

#	ARTICLE	IF	CITATIONS
379	Contemporary Age-adjusted Incidence and Mortality Rates of Renal Cell Carcinoma: Analysis According to Gender, Race, Stage, Grade, and Histology. <i>European Urology Focus</i> , 2021, 7, 644-652.	1.6	28
380	Pre-operative Percent Free PSA Predicts Clinical Outcomes in Patients Treated with Radical Prostatectomy with Total PSA Levels below 10ng/ml. <i>European Urology</i> , 2006, 49, 293-302.	0.9	27
381	Temporal stage and grade migration in surgically treated patients with upper tract urothelial carcinoma. <i>BJU International</i> , 2010, 105, 799-804.	1.3	27
382	Insulin-like Growth Factor Messenger RNA-binding Protein 3 Expression Helps Prognostication in Patients with Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2014, 66, 379-385.	0.9	27
383	Impact of Synchronous Metastasis Distribution on Cancer Specific Survival in Renal Cell Carcinoma after Radical Nephrectomy with Tumor Thrombectomy. <i>Journal of Urology</i> , 2015, 193, 436-442.	0.2	27
384	Pure but Not Mixed Histologic Variants Are Associated With Poor Survival at Radical Cystectomy in Bladder Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e603-e607.	0.9	27
385	Location of Metastases in Contemporary Prostate Cancer Patients Affects Cancer-Specific Mortality. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 376-384.e1.	0.9	27
386	Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 440-448.	0.8	27
387	Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 539-548.	2.0	27
388	Bladder Cancer: A Comparison Between Non-urothelial Variant Histology and Urothelial Carcinoma Across All Stages and Treatment Modalities. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 60-68.e1.	0.9	27
389	Penile Rehabilitation Strategy after Nerve Sparing Radical Prostatectomy: A Systematic Review and Network Meta-Analysis of Randomized Trials. <i>Journal of Urology</i> , 2021, 205, 1018-1030.	0.2	27
390	Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study. <i>European Urology</i> , 2021, 80, 507-515.	0.9	27
391	Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 16-22.	0.4	26
392	Preoperative Plasma HER2 and Epidermal Growth Factor Receptor for Staging and Prognostication in Patients with Clinically Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 5377-5384.	3.2	26
393	Impact of ABO Blood Type on Outcomes in Patients with Primary Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2014, 191, 1238-1243.	0.2	26
394	Validation of tertiary Gleason pattern 5 in Gleason score 7 prostate cancer as an independent predictor of biochemical recurrence and development of a prognostic model. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 71.e21-71.e26.	0.8	26
395	Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival. <i>Journal of Surgical Oncology</i> , 2016, 114, 764-768.	0.8	26
396	Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 167.e9-167.e16.	0.8	26

#	ARTICLE	IF	CITATIONS
397	Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. <i>World Journal of Urology</i> , 2017, 35, 327-335.	1.2	26
398	Preoperative nomogram to predict the likelihood of complications after radical nephroureterectomy. <i>BJU International</i> , 2017, 119, 268-275.	1.3	26
399	Systematic Review: Depression and Anxiety Prevalence in Bladder Cancer Patients. <i>Bladder Cancer</i> , 2018, 4, 319-326.	0.2	26
400	Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 77.e1-77.e7.	0.8	26
401	Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 774-782.	0.8	26
402	Penile rehabilitation after radical prostatectomy: does it work?. <i>Translational Andrology and Urology</i> , 2015, 4, 110-23.	0.6	26
403	En Bloc Resection for Bladder Tumors: An Updated Systematic Review and Meta-Analysis of Its Differential Effect on Safety, Recurrence and Histopathology. <i>Journal of Urology</i> , 2022, 207, 754-768.	0.2	26
404	Predictive tools for clinical decision-making and counseling of patients with upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2013, 31, 31-36.	1.2	25
405	Predictors of Survival in Patients With Soft Tissue Surgical Margin Involvement at Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2013, 20, 1027-1034.	0.7	25
406	Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 625-630.	0.8	25
407	ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy. <i>Journal of Urology</i> , 2015, 194, 1456-1462.	0.2	25
408	Pelvic Lymph Node Dissection in Prostate Cancer: Indications, Extent and Tailored Approaches. <i>Urologia</i> , 2017, 84, 9-19.	0.3	25
409	The interaction of gender and smoking on bladder cancer risks. <i>Current Opinion in Urology</i> , 2019, 29, 249-255.	0.9	25
410	Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies. <i>European Urology Oncology</i> , 2019, 2, 355-364.	2.6	25
411	Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 179.e19-179.e28.	0.8	25
412	Prognostic value of alkaline phosphatase in hormone-sensitive prostate cancer: a systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2020, 25, 247-257.	1.0	25
413	Prognostic value of preoperative hematologic biomarkers in urothelial carcinoma of the bladder treated with radical cystectomy: a systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1459-1474.	1.0	25
414	Association of erectile dysfunction and cardiovascular disease: an umbrella review of systematic reviews and meta-analyses. <i>BJU International</i> , 2021, 128, 3-11.	1.3	25

#	ARTICLE	IF	CITATIONS
415	Blood biomarkers for prostate cancer detection and prognosis. <i>Future Oncology</i> , 2007, 3, 449-461.	1.1	24
416	Pathologic Nodal Staging Scores in Patients Treated with Radical Prostatectomy: A Postoperative Decision Tool. <i>European Urology</i> , 2014, 66, 439-446.	0.9	24
417	Is there a relationship between leapfrog volume thresholds and perioperative outcomes after radical cystectomy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 27.e7-27.e13.	0.8	24
418	Robotic assisted simple prostatectomy. <i>Current Opinion in Urology</i> , 2018, 28, 309-314.	0.9	24
419	Prognostic Value of Lactate Dehydrogenase in Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 409-418.	0.9	24
420	Prognostic value of nutritional indices and body composition parameters including sarcopenia in patients treated with radiotherapy for urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 372-379.	0.8	24
421	First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 151, 35-48.	1.3	24
422	Upper urinary tract disease: what we know today and unmet needs. <i>Translational Andrology and Urology</i> , 2015, 4, 261-72.	0.6	24
423	Gastrointestinal hemorrhage as first manifestation of metastatic testicular tumor. <i>Urology</i> , 2005, 66, 1319.e21-1319.e24.	0.5	23
424	Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin. <i>Urology Annals</i> , 2011, 3, 119.	0.3	23
425	Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with Mitomycin C in superficial transitional cell carcinoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 503-509.	1.1	23
426	Cytoreductive radical prostatectomy in metastatic prostate cancer: Does it really make sense?. <i>World Journal of Urology</i> , 2017, 35, 567-577.	1.2	23
427	PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 43-46.	0.3	23
428	Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 312.e9-312.e15.	0.8	23
429	Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis. <i>World Journal of Urology</i> , 2018, 36, 7-13.	1.2	23
430	Is it worth to perform salvage radical prostatectomy for radio-recurrent prostate cancer? A literature review. <i>World Journal of Urology</i> , 2019, 37, 1469-1483.	1.2	23
431	Rates of Positive Surgical Margins and Their Effect on Cancer-specific Mortality at Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e130-e139.	0.9	23
432	Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis. <i>World Journal of Urology</i> , 2020, 38, 1437-1449.	1.2	23

#	ARTICLE	IF	CITATIONS
433	Cryoablation Predisposes to Higher Cancer Specific Mortality Relative to Partial Nephrectomy in Patients with Nonmetastatic pT1b Kidney Cancer. <i>Journal of Urology</i> , 2019, 202, 1120-1126.	0.2	23
434	Plasminogen Activation Inhibitor-1 Improves the Predictive Accuracy of Prostate Cancer Nomograms. <i>Journal of Urology</i> , 2007, 178, 1229-1237.	0.2	22
435	Prognostic effect of serum and tissue YKL-40 levels in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 663-669.	0.8	22
436	A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2016, 48, 25-33.	3.4	22
437	Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 233.e1-233.e6.	0.8	22
438	Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. <i>World Journal of Urology</i> , 2017, 35, 113-120.	1.2	22
439	Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice. <i>BJU International</i> , 2018, 121, 84-92.	1.3	22
440	Combination of High-Resolution Optical Coherence Tomography and Raman Spectroscopy for Improved Staging and Grading in Bladder Cancer. <i>Applied Sciences (Switzerland)</i> , 2018, 8, 2371.	1.3	22
441	High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study. <i>Urologia Internationalis</i> , 2018, 101, 7-15.	0.6	22
442	Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database. <i>European Urology Focus</i> , 2019, 5, 807-814.	1.6	22
443	The rational and benefits of the second look transurethral resection of the bladder for T1 high grade bladder cancer. <i>Translational Andrology and Urology</i> , 2019, 8, 46-53.	0.6	22
444	Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases. <i>World Journal of Urology</i> , 2020, 38, 1959-1968.	1.2	22
445	Impact of Patients' Gender on Efficacy of Immunotherapy in Patients With Metastatic Kidney Cancer: A Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 88-94.e2.	0.9	22
446	Unmarried men have worse oncologic outcomes after radical cystectomy for nonmetastatic urothelial bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 76.e1-76.e9.	0.8	22
447	Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 573-580.	2.0	22
448	Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer. <i>BJU International</i> , 2021, 127, 44-55.	1.3	22
449	Frailty impact on postoperative complications and early mortality rates in patients undergoing radical cystectomy for bladder cancer: a systematic review. <i>Arab Journal of Urology Arab Association of Urology</i> , 2021, 19, 9-23.	0.7	22
450	Upper Urinary Tract Tumors: Variant Histology Versus Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 117-124.	0.9	22

#	ARTICLE	IF	CITATIONS
451	Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups. <i>International Journal of Urology</i> , 2021, 28, 862-869.	0.5	22
452	Risk factors associated with positive surgical margins location at radical cystectomy and their impact on bladder cancer survival. <i>World Journal of Urology</i> , 2021, 39, 4363-4371.	1.2	22
453	The Prognostic Association of Prostate MRI PI-RADS v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2021, 206, 507-516.	0.2	22
454	Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 110.e1-110.e9.	0.8	22
455	Update on intravesical agents for non-muscle-invasive bladder cancer. <i>Immunotherapy</i> , 2010, 2, 381-392.	1.0	21
456	Low-Coverage Exome Sequencing Screen in Formalin-Fixed Paraffin-Embedded Tumors Reveals Evidence of Exposure to Carcinogenic Aristolochic Acid. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1873-1881.	1.1	21
457	Suboptimal use of neoadjuvant chemotherapy in radical cystectomy patients: A population-based study. <i>Canadian Urological Association Journal</i> , 2016, 10, 82.	0.3	21
458	The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 659-671.	0.8	21
459	Rates of lymph node invasion and their impact on cancer specific mortality in upper urinary tract urothelial carcinoma. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1238-1245.	0.5	21
460	Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years. <i>European Urology Focus</i> , 2019, 5, 467-473.	1.6	21
461	Complication rates, failure to rescue and in-hospital mortality after cytoreductive nephrectomy in the older patients. <i>Journal of Geriatric Oncology</i> , 2020, 11, 718-723.	0.5	21
462	Prognostic role of the systemic immune-inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2641-2650.	2.0	21
463	Systematic Review of the Impact of Testosterone Replacement Therapy on Depression in Patients with Late-onset Testosterone Deficiency. <i>European Urology Focus</i> , 2020, 6, 170-177.	1.6	21
464	The Prognostic Impact of Intraductal Carcinoma of the Prostate: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2020, 204, 909-917.	0.2	21
465	Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy. <i>BJU International</i> , 2007, 101, 070916224627004-???	1.3	20
466	Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 256.e7-256.e13.	0.8	20
467	Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2021, 39, 1757-1768.	1.2	20
468	Contemporary conditional cancer-specific survival after radical nephroureterectomy in patients with nonmetastatic urothelial carcinoma of upper urinary tract. <i>Journal of Surgical Oncology</i> , 2020, 121, 1154-1161.	0.8	20

#	ARTICLE	IF	CITATIONS
469	The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. <i>Advances in Anatomic Pathology</i> , 2021, 28, 196-208.	2.4	20
470	Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer. <i>Translational Andrology and Urology</i> , 2021, 10, 626-635.	0.6	20
471	Discordance Between Clinical and Pathological Staging and Grading in Upper Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 95.e1-95.e6.	0.9	20
472	Concomitant Carcinoma in situ in Cystectomy Specimens Is Not Associated with Clinical Outcomes after Surgery. <i>Urologia Internationalis</i> , 2011, 87, 42-48.	0.6	19
473	Association of Oncofetal Protein Expression with Clinical Outcomes in Patients with Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2014, 191, 830-841.	0.2	19
474	Development of a Preoperative Nomogram Incorporating Biomarkers of Systemic Inflammatory Response to Predict Nonorgan-confined Urothelial Carcinoma of the Bladder at Radical Cystectomy. <i>Urology</i> , 2016, 95, 132-138.	0.5	19
475	Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 485.e7-485.e14.	0.8	19
476	External Validation of Bladder Cancer Predictive Nomograms for Recurrence, Cancer-Free Survival and Overall Survival following Radical Cystectomy. <i>Journal of Urology</i> , 2016, 195, 283-289.	0.2	19
477	Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma. <i>Cancer Epidemiology</i> , 2018, 56, 118-125.	0.8	19
478	Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database. <i>European Urology Oncology</i> , 2018, 1, 314-320.	2.6	19
479	Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer. <i>European Urology</i> , 2018, 74, 693-696.	0.9	19
480	Prognostic Value of Serum Cholinesterase in Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1123-e1132.	0.9	19
481	Contemporary Incidence and Mortality Rates in Patients With Testicular Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e1026-e1035.	0.9	19
482	Impact of Gender on Chemotherapeutic Response and Oncologic Outcomes in Patients Treated With Radical Cystectomy and Perioperative Chemotherapy for Bladder Cancer: A Systematic Review and Meta-Analysis. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 78-87.	0.9	19
483	Impact of Smoking Habit on Perioperative Morbidity in Patients Treated with Radical Cystectomy for Urothelial Bladder Cancer: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2021, 4, 580-593.	2.6	19
484	Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical nephroureterectomy. <i>Journal of Surgical Oncology</i> , 2020, 121, 688-696.	0.8	19
485	Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2022, 40, 907-914.	1.2	19
486	Differential Effect of Sex on Outcomes after Radical Surgery for Upper Tract and Bladder Urothelial Carcinoma: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2020, 204, 58-62.	0.2	19

#	ARTICLE	IF	CITATIONS
487	Anomalies of the wolffian duct derivatives encountered at radical prostatectomy. <i>Reviews in Urology</i> , 2005, 7, 75-80.	0.9	19
488	Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2022, 27, 59-71.	1.0	19
489	Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis. <i>Archivos Espanoles De Urologia</i> , 2011, 64, 681-94.	0.1	19
490	Postoperative nomogram for disease recurrence and cancer-specific death for upper tract urothelial carcinoma: comparison to American Joint Committee on Cancer staging classification. <i>Urology Journal</i> , 2014, 11, 1435-41.	0.3	19
491	Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 490.e13-490.e20.	0.8	19
492	Evaluation of the Prognostic Significance of Altered Mammalian Target of Rapamycin Pathway Biomarkers in Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2014, 84, 1134-1140.	0.5	18
493	Comparative analysis of comorbidity and performance indices for prediction of oncological outcomes in patients with upper tract urothelial carcinoma who were treated with radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1141-1150.	0.8	18
494	How to optimally manage elderly bladder cancer patients?. <i>Translational Andrology and Urology</i> , 2016, 5, 683-691.	0.6	18
495	Surgical treatment for clinical node-positive bladder cancer patients treated with radical cystectomy without neoadjuvant chemotherapy. <i>World Journal of Urology</i> , 2018, 36, 639-644.	1.2	18
496	Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis. <i>European Urology Focus</i> , 2018, 4, 252-259.	1.6	18
497	Prevention of bladder cancer incidence and recurrence. <i>Current Opinion in Urology</i> , 2018, 28, 80-87.	0.9	18
498	What to do during Bacillus Calmette-Guérin shortage? Valid strategies based on evidence. <i>Current Opinion in Urology</i> , 2018, 28, 570-576.	0.9	18
499	The impact of moderate wine consumption on the risk of developing prostate cancer. <i>Clinical Epidemiology</i> , 2018, Volume 10, 431-444.	1.5	18
500	Postoperative paralytic ileus after major oncological procedures in the enhanced recovery after surgery era: A population based analysis. <i>Surgical Oncology</i> , 2019, 28, 201-207.	0.8	18
501	Association of an organ transplant-based approach with a dramatic reduction in postoperative complications following radical nephrectomy and tumor thrombectomy in renal cell carcinoma. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1983-1992.	0.5	18
502	Bladder Cancer: Depression, Anxiety, and Suicidality Among the Highest-risk Oncology Patients. <i>European Urology Focus</i> , 2020, 6, 1158-1161.	1.6	18
503	Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 20-25.e2.	0.9	18
504	Secretion of severe acute respiratory syndrome coronavirus 2 in urine. <i>Current Opinion in Urology</i> , 2020, Publish Ahead of Print, 735-739.	0.9	18

#	ARTICLE	IF	CITATIONS
505	Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 3345-3352.	1.2	18
506	Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 4355-4361.	1.2	18
507	Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. <i>Journal of Urology</i> , 2022, 207, 375-384.	0.2	18
508	Diagnosis and Management of Upper Tract Urothelial Carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 271-288.	0.9	17
509	The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 533.e1-533.e10.	0.8	17
510	Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma. <i>World Journal of Urology</i> , 2016, 34, 1429-1436.	1.2	17
511	The Moreau Strain of Bacillus Calmette-Guerin (BCG) for High-Risk Non-Muscle Invasive Bladder Cancer: An Alternative during Worldwide BCG Shortage?. <i>Urologia Internationalis</i> , 2016, 96, 46-50.	0.6	17
512	Neoadjuvant and adjuvant treatment in high-risk prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 425-438.	1.3	17
513	Survival and Complication Rates of Metastasectomy in Patients With Metastatic Renal Cell Carcinoma Treated Exclusively With Targeted Therapy: A Combined Population-based Analysis. <i>Anticancer Research</i> , 2019, 39, 4357-4361.	0.5	17
514	Survival Effect of Nephroureterectomy in Metastatic Upper Urinary Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e602-e611.	0.9	17
515	Smoking and bladder cancer: review of the recent literature. <i>Current Opinion in Urology</i> , 2020, 30, 720-725.	0.9	17
516	Thyroid and androgen receptor signaling are antagonized by Î³4â€œCrystallin in prostate cancer. <i>International Journal of Cancer</i> , 2021, 148, 731-747.	2.3	17
517	Tumor Size Predicts Muscle-invasive and Nonâ€œorgan-confined Disease in Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy. <i>European Urology Focus</i> , 2022, 8, 498-505.	1.6	17
518	Impact of enhanced optical techniques at time of transurethral resection of bladder tumour, with or without single immediate intravesical chemotherapy, on recurrence rate of nonâ€œmuscleâ€œinvasive bladder cancer: a systematic review and network metaâ€œanalysis of randomized trials. <i>BJU International</i> , 2021, 128, 280-289.	1.3	17
519	Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 409-421.	0.8	17
520	Renal Cell Carcinoma: Comparison between Variant Histology and Clear Cell Carcinoma across All Stages and Treatment Modalities. <i>Journal of Urology</i> , 2020, 204, 671-676.	0.2	17
521	Urinary Levels of Tumor-Associated Trypsin Inhibitor (TATI) in the Detection of Transitional Cell Carcinoma of the Urinary Bladder. <i>European Urology</i> , 2005, 48, 424-431.	0.9	16
522	Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multiâ€œinstitutional study. <i>BJU International</i> , 2017, 119, 234-238.	1.3	16

#	ARTICLE	IF	CITATIONS
523	Contemporary rates of pathological features and mortality for adenocarcinoma of the urinary bladder in the USA. <i>International Journal of Urology</i> , 2017, 24, 117-123.	0.5	16
524	Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 176-183.	0.9	16
525	Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer. <i>World Journal of Urology</i> , 2018, 36, 1399-1407.	1.2	16
526	Pattern of node metastases in patients treated with radical cystectomy and extended or superextended pelvic lymph node dissection due to bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 307.e9-307.e14.	0.8	16
527	Predictors of Cancer-specific Survival After Disease Recurrence in Patients With Renal Cell Carcinoma: The Effect of Time to Recurrence. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e903-e908.	0.9	16
528	Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy. <i>World Journal of Urology</i> , 2018, 36, 51-57.	1.2	16
529	Elevated preoperative neutrophil-lymphocyte ratio predicts upgrading at radical prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 100-105.	2.0	16
530	Location of Metastatic Bladder Cancer as a Determinant of In-hospital Mortality After Radical Cystectomy. <i>European Urology Oncology</i> , 2018, 1, 169-175.	2.6	16
531	Long-term incidence of secondary bladder and rectal cancer in patients treated with brachytherapy for localized prostate cancer: a large-scale population-based analysis. <i>BJU International</i> , 2019, 124, 1006-1013.	1.3	16
532	Nephroureterectomy with or without Bladder Cuff Excision for Localized Urothelial Carcinoma of the Renal Pelvis. <i>European Urology Focus</i> , 2020, 6, 298-304.	1.6	16
533	Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series. <i>European Urology</i> , 2020, 78, 779-782.	0.9	16
534	A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma. <i>BJU International</i> , 2022, 129, 182-193.	1.3	16
535	Contemporary patterns of presentation, diagnostics and management of upper tract urothelial cancer in 101 centres: the Clinical Research Office of the Endourological Society Global upper tract urothelial carcinoma registry. <i>Current Opinion in Urology</i> , 2021, 31, 354-362.	0.9	16
536	Intracorporeal versus extracorporeal urinary diversion in robot-assisted radical cystectomy: a systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1587-1599.	1.0	16
537	Salvage Radical Prostatectomy for Radio-Recurrent Prostate Cancer: An Updated Systematic Review of Oncologic, Histopathologic and Functional Outcomes and Predictors of Good Response. <i>Current Oncology</i> , 2021, 28, 2881-2892.	0.9	16
538	Rectal preparation significantly improves prostate imaging quality: Assessment of the PI-QUAL score with visual grading characteristics. <i>European Journal of Radiology</i> , 2022, 147, 110145.	1.2	16
539	Soluble gp130 Regulates Prostate Cancer Invasion and Progression in an Interleukin-6 Dependent and Independent Manner. <i>Journal of Urology</i> , 2011, 186, 2107-2114.	0.2	15
540	Highlights from the first symposium on upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 309-316.	0.8	15

#	ARTICLE	IF	CITATIONS
541	Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: A multi-institutional study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 495.e15-495.e22.	0.8	15
542	Predictive models and prognostic factors for upper tract urothelial carcinoma: a comprehensive review of the literature. <i>Translational Andrology and Urology</i> , 2016, 5, 720-734.	0.6	15
543	Population-based assessment of cancer-specific mortality after local tumour ablation or observation for kidney cancer: a competing risks analysis. <i>BJU International</i> , 2016, 118, 541-546.	1.3	15
544	Serum Adiponectin Predicts Cancer-specific Survival of Patients with Renal Cell Carcinoma. <i>European Urology Focus</i> , 2016, 2, 197-203.	1.6	15
545	Comparison of Postoperative Complications and Mortality Between Laparoscopic and Percutaneous Local Tumor Ablation for T1a Renal Cell Carcinoma: A Population-based Study. <i>Urology</i> , 2016, 89, 63-68.	0.5	15
546	A proposal of a new nomogram for predicting upstaging in contemporary Dâ€™Amico low-risk prostate cancer patients. <i>World Journal of Urology</i> , 2017, 35, 189-197.	1.2	15
547	North American Population-Based Validation of the National Comprehensive Cancer Network Practice Guideline Recommendation of Pelvic Lymphadenectomy in Contemporary Prostate Cancer. <i>Prostate</i> , 2017, 77, 542-548.	1.2	15
548	Perioperative Allogenic Blood Transfusion in Renal Cell Carcinoma: Risk Factors and Effect on Long-term Outcomes. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e421-e427.	0.9	15
549	Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy. <i>World Journal of Urology</i> , 2018, 36, 1775-1781.	1.2	15
550	Oncologic outcomes after robot-assisted versus open radical cystectomy: a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2019, 37, 1557-1570.	1.2	15
551	The impact of gender on oncologic outcomes of bladder cancer. <i>Current Opinion in Urology</i> , 2019, 29, 279-285.	0.9	15
552	More Extensive Lymph Node Dissection Improves Survival Benefit of Radical Cystectomy in Metastatic Urothelial Carcinoma of the Bladder. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 105-113.e2.	0.9	15
553	Is neoadjuvant chemotherapy for pT2 bladder cancer associated with a survival benefit in a population-based analysis?. <i>Cancer Epidemiology</i> , 2019, 58, 83-88.	0.8	15
554	Prognostic Value of Hemoglobin in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e402-e409.	0.9	15
555	Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer. <i>Current Opinion in Urology</i> , 2020, 30, 519-526.	0.9	15
556	Trends in Sexual Activity and Associations with All-Cause and Cause-Specific Mortality Among US Adults. <i>Journal of Sexual Medicine</i> , 2020, 17, 1903-1913.	0.3	15
557	Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 639.e1-639.e9.	0.8	15
558	Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 600.e9-600.e15.	0.8	15

#	ARTICLE	IF	CITATIONS
559	Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis. <i>World Journal of Urology</i> , 2021, 39, 461-472.	1.2	15
560	Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific Validation. <i>European Urology Focus</i> , 2022, 8, 182-190.	1.6	15
561	Incidence rates and contemporary trends in primary urethral cancer. <i>Cancer Causes and Control</i> , 2021, 32, 627-634.	0.8	15
562	Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2022, 207, 70-76.	0.2	15
563	Vesical Imaging Reporting and Data System (VI-RADS): Are the individual MRI sequences equivalent in diagnostic performance of high grade NMIBC and MIBC?. <i>European Journal of Radiology</i> , 2021, 142, 109829.	1.2	15
564	Contemporary Trends of Systemic Neoadjuvant and Adjuvant Intravesical Chemotherapy in Patients With Upper Tract Urothelial Carcinomas Undergoing Minimally Invasive or Open Radical Nephroureterectomy: Analysis of US Claims on Perioperative Outcomes and Health Care Costs. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 198.e1-198.e9.	0.9	15
565	Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2022, 82, 82-96.	0.9	15
566	Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 315-330.	0.8	15
567	Adrenal Ganglioneuroma with Multifocal Retroperitoneal Extension: A Challenging Diagnosis. <i>Scientific World Journal</i> , The, 2011, 11, 1548-1553.	0.8	14
568	Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study. <i>BJU International</i> , 2016, 118, 243-249.	1.3	14
569	Impact of Perioperative Allogenic Blood Transfusion on Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 96-104.	0.9	14
570	Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 528.e1-528.e5.	0.8	14
571	Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1039-e1045.	0.9	14
572	Novel endoscopic visualization techniques for bladder cancer detection. <i>Current Opinion in Urology</i> , 2018, 28, 214-218.	0.9	14
573	Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 79.e11-79.e17.	0.8	14
574	Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer. <i>Current Opinion in Urology</i> , 2018, 28, 577-583.	0.9	14
575	Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2018, 1, 283-291.	2.6	14
576	How cancer-specific mortality changes over time after radical cystectomy: Conditional survival of patients with nonmetastatic urothelial carcinoma of the urinary bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 893-899.	0.8	14

#	ARTICLE	IF	CITATIONS
577	Role of lasers in urology. <i>Photochemical and Photobiological Sciences</i> , 2019, 18, 295-303.	1.6	14
578	The impact of variant histological differentiation on extranodal extension and survival in node positive bladder cancer treated with radical cystectomy. <i>Surgical Oncology</i> , 2019, 28, 208-213.	0.8	14
579	The effect of age and comorbidities on early postoperative complications after radical cystectomy: A contemporary population-based analysis. <i>Journal of Geriatric Oncology</i> , 2019, 10, 623-631.	0.5	14
580	Intravesical bacillus Calmette-Guérin for bladder cancer: are all the strains equal?. <i>Translational Andrology and Urology</i> , 2019, 8, 85-93.	0.6	14
581	Optimal Management of Upper Tract Urothelial Carcinoma: an Unmet Need. <i>Current Treatment Options in Oncology</i> , 2019, 20, 40.	1.3	14
582	Enhanced Recovery after Radical Cystectomy. <i>Current Opinion in Urology</i> , 2019, 29, 227-238.	0.9	14
583	The Performance of Tumor Size as Risk Stratification Parameter in Upper Tract Urothelial Carcinoma (UTUC). <i>Clinical Genitourinary Cancer</i> , 2021, 19, 272.e1-272.e7.	0.9	14
584	Stratification of Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: Implications for Adjuvant Therapies. <i>European Urology Focus</i> , 2020, 7, 566-573.	1.6	14
585	Renal cell carcinoma incidence rates and trends in young adults aged 20-39 years. <i>Cancer Epidemiology</i> , 2020, 67, 101762.	0.8	14
586	Catalog of exogenous risk factors for bladder carcinogenesis. <i>Current Opinion in Urology</i> , 2020, 30, 449-456.	0.9	14
587	Impact of systemic Immune-inflammatory Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 785.e19-785.e27.	0.8	14
588	Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 764-773.	0.8	14
589	Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 1072-1089.	1.6	14
590	Radiofrequency Ablation for Renal Cancer in Von Hippel-Lindau Syndrome Patients: A Prospective Cohort Analysis. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 28-34.	0.9	14
591	Assessment of local tumor ablation and non-interventional management versus partial nephrectomy in T1a renal cell carcinoma. <i>Minerva Urologica e Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 350-359.	3.9	14
592	Conditional Survival of Patients With Nonmetastatic Renal Cell Carcinoma: How Cancer-Specific Mortality Changes After Nephrectomy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 44-51.	2.3	14
593	Role of cigarette smoking in urological malignancies and clinical interventions for smoking cessation. <i>Central European Journal of Urology</i> , 2016, 69, 366-369.	0.2	14
594	Impact of preoperative systemic immune-inflammatory Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 106.e11-106.e19.	0.8	14

#	ARTICLE	IF	CITATIONS
595	Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Surgery</i> , 2021, 8, 775527.	0.6	14
596	Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette-Guerin Immunotherapy. <i>Diagnostics</i> , 2022, 12, 586.	1.3	14
597	Update on ablative therapies of renal tumors. <i>Current Opinion in Urology</i> , 2016, 26, 410-416.	0.9	13
598	Dynamic Prognostication Using Conditional Recurrence and Progression Estimates for Patients with Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2016, 196, 46-51.	0.2	13
599	Circulating and Tissue Expression Levels of YKL-40 in Renal Cell Cancer. <i>Journal of Urology</i> , 2016, 195, 1120-1125.	0.2	13
600	The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 151.e17-151.e23.	0.8	13
601	A contemporary analysis of radiotherapy effect in surgically treated retroperitoneal sarcoma. <i>Radiotherapy and Oncology</i> , 2018, 127, 318-325.	0.3	13
602	Prognostic Role of N-cadherin Expression in Patients With Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e73-e78.	0.9	13
603	Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma. <i>Cancer Epidemiology</i> , 2018, 54, 112-118.	0.8	13
604	The effect of age on cancer-specific mortality in patients with small renal masses: A population-based analysis. <i>Canadian Urological Association Journal</i> , 2018, 12, E325-30.	0.3	13
605	Diagnosis and kidney-sparing treatments for upper tract urothelial carcinoma: state of the art. <i>Minerva Urology and Nephrology</i> , 2018, 70, 242-251.	1.3	13
606	Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes. <i>Journal of Clinical Medicine</i> , 2019, 8, 1192.	1.0	13
607	Regional differences in total hospital charges between open and robotically assisted radical prostatectomy in the United States. <i>World Journal of Urology</i> , 2019, 37, 1305-1313.	1.2	13
608	Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 537-544.	0.8	13
609	The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration. <i>World Journal of Urology</i> , 2021, 39, 443-451.	1.2	13
610	Value of tumour-infiltrating immune cells in predicting response to intravesical BCG in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis. <i>BJU International</i> , 2021, 127, 617-625.	1.3	13
611	The effect of lymph node dissection on cancer-specific survival in salvage radical prostatectomy patients. <i>Prostate</i> , 2021, 81, 339-346.	1.2	13
612	Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study. <i>European Urology Focus</i> , 2022, 8, 491-497.	1.6	13

#	ARTICLE	IF	CITATIONS
613	Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102242.	3.4	13
614	The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis. <i>International Immunopharmacology</i> , 2022, 108, 108720.	1.7	13
615	Do we need repeat <sc>transurethral resection</sc> after <i>en bloc</i> resection for <sc>pathological T1</sc> bladder cancer?. <i>BJU International</i> , 2023, 131, 190-197.	1.3	13
616	Associations Between Presenting Symptoms, Clinicopathological Parameters, and Prognosis in a Contemporary Series of Patients With Renal Cell Carcinoma. <i>Korean Journal of Urology</i> , 2014, 55, 505.	1.2	12
617	Predictors of Cancer-specific Mortality After Disease Recurrence in Patients with Squamous Cell Carcinoma of the Penis. <i>European Urology</i> , 2014, 66, 811-814.	0.9	12
618	Partial nephrectomy for renal tumors in solitary kidneys: postoperative renal function dynamics. <i>World Journal of Urology</i> , 2015, 33, 2023-2029.	1.2	12
619	Current perspectives of sentinel lymph node dissection at the time of radical surgery for prostate cancer. <i>Cancer Treatment Reviews</i> , 2016, 50, 228-239.	3.4	12
620	Immune therapy meets precision medicine. <i>Lancet Oncology</i> , The, 2017, 18, 271-273.	5.1	12
621	Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study. <i>World Journal of Urology</i> , 2017, 35, 1073-1080.	1.2	12
622	Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy. <i>Bladder Cancer</i> , 2017, 3, 161-169.	0.2	12
623	Waiting in the wings: the emerging role of molecular biomarkers in bladder cancer. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 347-356.	1.5	12
624	The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients. <i>European Urology Oncology</i> , 2018, 1, 215-222.	2.6	12
625	The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer. <i>Urologia Internationalis</i> , 2018, 101, 65-73.	0.6	12
626	Sarcopenia as a Predictive Factor for Response to Upfront Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Urothelial Bladder Cancer. <i>Urologia Internationalis</i> , 2018, 101, 197-200.	0.6	12
627	Unmarried status is a barrier for access to treatment in patients with metastatic renal cell carcinoma. <i>International Urology and Nephrology</i> , 2019, 51, 2181-2188.	0.6	12
628	Do Younger Patients with Muscle-Invasive Bladder Cancer have Better Outcomes?. <i>Journal of Clinical Medicine</i> , 2019, 8, 1459.	1.0	12
629	Impact of alcohol consumption on the risk of developing bladder cancer: a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2019, 37, 2313-2324.	1.2	12
630	Impact of Tumor Size on Cancer-Specific Mortality Rate After Local Tumor Ablation in T1a Renal-Cell Carcinoma. <i>Journal of Endourology</i> , 2019, 33, 606-613.	1.1	12

#	ARTICLE	IF	CITATIONS
631	Perioperative blood transfusion affects oncologic outcomes after nephrectomy for renal cell carcinoma: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 273-281.	0.8	12
632	Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients. <i>European Urology Focus</i> , 2019, 5, 381-388.	1.6	12
633	Aristolochic acid and its effect on different cancers in uro-oncology. <i>Current Opinion in Urology</i> , 2020, 30, 689-695.	0.9	12
634	Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer. <i>Current Opinion in Urology</i> , 2020, 30, 547-556.	0.9	12
635	Prognostic role of preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 601.e17-601.e24.	0.8	12
636	Performance of fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography imaging for lymph node staging in bladder and upper tract urothelial carcinoma: a systematic review. <i>Arab Journal of Urology Arab Association of Urology</i> , 2021, 19, 59-66.	0.7	12
637	Placebo Response in Patients with Oral Therapy for Overactive Bladder: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 239-252.	1.6	12
638	Pattern of Biopsy Gleason Grade Group 5 (4 + 5 vs 5 + 4 vs 5 + 5) Predicts Survival After Radical Prostatectomy or External Beam Radiation Therapy. <i>European Urology Focus</i> , 2022, 8, 710-717.	1.6	12
639	Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer. <i>Journal of Urology</i> , 2021, 206, 69-79.	0.2	12
640	Association between Inflammatory Potential of Diet and Bladder Cancer Risk: Results of 3 United States Prospective Cohort Studies. <i>Journal of Urology</i> , 2019, 202, 484-489.	0.2	12
641	Phase III study of pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus CRT alone for patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-992.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS5093-TPS5093.	0.8	12
642	Impact of the Ki-67 labeling index and p53 expression status on disease-free survival in pT1 urothelial carcinoma of the bladder. <i>Translational Andrology and Urology</i> , 2017, 6, 1018-1026.	0.6	12
643	Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis. <i>Cancers</i> , 2022, 14, 887.	1.7	12
644	Re-assessment of 30-, 60- and 90-day mortality rates in non-metastatic prostate cancer patients treated either with radical prostatectomy or radiation therapy. <i>Canadian Urological Association Journal</i> , 2014, 8, 75.	0.3	11
645	Preoperative Favorable Characteristics in Bladder Cancer Patients Cannot Substitute the Necessity of Extended Lymphadenectomy During Radical Cystectomy: A Sensitivity Curve Analysis. <i>Urology</i> , 2016, 88, 97-103.	0.5	11
646	The impact of local treatment of the primary tumor site in node positive and metastatic prostate cancer patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 7-11.	2.0	11
647	Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 386-393.	2.0	11
648	Oncologic outcomes after minimally invasive surgery for cT1 renal masses. <i>Current Opinion in Urology</i> , 2018, 28, 132-138.	0.9	11

#	ARTICLE	IF	CITATIONS
649	Contemporary rates of adherence to international guidelines for pelvic lymph node dissection in radical cystectomy: a population-based study. <i>World Journal of Urology</i> , 2018, 36, 1417-1422.	1.2	11
650	Comparison of Perioperative Outcomes Between Open and Robotic Radical Cystectomy: A Population-Based Analysis. <i>Journal of Endourology</i> , 2018, 32, 701-709.	1.1	11
651	Progressive tissue biomarker profiling in non-muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 695-703.	1.1	11
652	The evolving role of percutaneous biopsy in renal masses. <i>Current Opinion in Urology</i> , 2018, 28, 364-368.	0.9	11
653	Cost analysis of prostate cancer detection including the prostate health index (phi). <i>World Journal of Urology</i> , 2019, 37, 481-487.	1.2	11
654	Comparison of perioperative outcomes between open and minimally invasive nephroureterectomy: A population-based analysis. <i>International Journal of Urology</i> , 2019, 26, 487-492.	0.5	11
655	Salvage therapeutic strategies for bacillus Calmette-Guérin failure. <i>Current Opinion in Urology</i> , 2019, 29, 239-246.	0.9	11
656	A Head-to-head Comparison of Four Prognostic Models for Prediction of Lymph Node Invasion in African American and Caucasian Individuals. <i>European Urology Focus</i> , 2019, 5, 449-456.	1.6	11
657	Partial Cystectomy With Pelvic Lymph Node Dissection for Patients With Nonmetastatic Stage pT2-T3 Urothelial Carcinoma of Urinary Bladder: Temporal Trends and Survival Outcomes. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 129-137.e3.	0.9	11
658	A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 314-321.e1.	0.9	11
659	Discovery of Molecular DNA Methylation-Based Biomarkers through Genome-Wide Analysis of Response Patterns to BCG for Bladder Cancer. <i>Cells</i> , 2020, 9, 1839.	1.8	11
660	Where do urologists stand in the era of novel coronavirus-2019 disease. <i>Current Opinion in Urology</i> , 2020, 30, 610-616.	0.9	11
661	An overview of current and emerging diagnostic, staging and prognostic markers for prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 841-850.	1.5	11
662	The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 739.e9-739.e15.	0.8	11
663	Prognostic value of the systemic inflammation modified Glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaboration. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 602.e11-602.e19.	0.8	11
664	Prognostic Value of Gleason Score at Positive Surgical Margin in Prostate Cancer: A Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e517-e522.	0.9	11
665	Predicting the risk of pT3a stage in cT1 clear cell renal cell carcinoma. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1187-1190.	0.5	11
666	Sex- and age-related differences in the distribution of bladder cancer metastases. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 976-983.	0.6	11

#	ARTICLE	IF	CITATIONS
667	Association Between Body Fat Mass and Kidney Stones in US Adults: Analysis of the National Health and Nutrition Examination Survey 2011–2018. <i>European Urology Focus</i> , 2021, , .	1.6	11
668	Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy. <i>Prostate</i> , 2021, 81, 728-735.	1.2	11
669	Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria. <i>Journal of Urology</i> , 2021, 205, 1387-1393.	0.2	11
670	Health-related quality of life in bladder cancer patients: bladder cancer-specific instruments and domains. Part 2. <i>Current Opinion in Urology</i> , 2021, 31, 304-314.	0.9	11
671	Nomogram Predicting Downgrading in National Comprehensive Cancer Network High-risk Prostate Cancer Patients Treated with Radical Prostatectomy. <i>European Urology Focus</i> , 2022, 8, 1133-1140.	1.6	11
672	Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration. <i>European Urology Focus</i> , 2022, 8, 1270-1277.	1.6	11
673	Oncologic Surveillance for Variant Histology Bladder Cancer after Radical Cystectomy. <i>Journal of Urology</i> , 2021, 206, 885-893.	0.2	11
674	Comparison of Clinicopathologic and Oncological Outcomes Between Transurethral En Bloc Resection and Conventional Transurethral Resection of Bladder Tumor: A Systematic Review, Meta-Analysis, and Network Meta-Analysis with Focus on Different Energy Sources. <i>Journal of Endourology</i> , 2022, 36, 535-547.	1.1	11
675	Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103570.	2.0	11
676	Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors. <i>European Urology Oncology</i> , 2022, 5, 30-41.	2.6	11
677	Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound. <i>European Urology</i> , 2022, 82, 261-270.	0.9	11
678	Oncologic Surveillance After Radical Nephroureterectomy for High-risk Upper Tract Urothelial Carcinoma. <i>European Urology Oncology</i> , 2022, 5, 451-459.	2.6	11
679	Two Cases of Retroperitoneal Metastasis from a Completely Regressed Burned-Out Testicular Cancer. <i>Urologia</i> , 2013, 80, 74-79.	0.3	10
680	Local tumor destruction in renal cell carcinoma—An inpatient population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 54.e1-54.e7.	0.8	10
681	Incidence and Predictors of 30-Day Readmission in Patients Treated With Radical Cystectomy: A Single Center European Experience. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e341-e346.	0.9	10
682	Impact of smoking status on survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>World Journal of Urology</i> , 2016, 34, 1411-1419.	1.2	10
683	External validation of the pathological nodal staging score in upper tract urothelial carcinoma: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 33.e21-33.e26.	0.8	10
684	Obesity is associated with biochemical recurrence after radical prostatectomy: A multi-institutional extended validation study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 460.e1-460.e8.	0.8	10

#	ARTICLE	IF	CITATIONS
685	Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 158.e1-158.e6.	0.8	10
686	North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients. <i>British Journal of Cancer</i> , 2018, 119, 1552-1556.	2.9	10
687	Contemporary analysis of the effect of marital status on survival of prostate cancer patients across all stages: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 702-710.	0.8	10
688	Role of serum cholinesterase in patients treated with salvage radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 123-129.	0.8	10
689	Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active Surveillance: A North American Population-Based Study. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 72-78.e4.	0.9	10
690	Association of super-extended lymphadenectomy at radical cystectomy with perioperative complications and re-hospitalization. <i>World Journal of Urology</i> , 2020, 38, 121-128.	1.2	10
691	Conditional survival of patients with stage III squamous cell carcinoma of the penis: temporal changes in cancer-specific mortality. <i>World Journal of Urology</i> , 2020, 38, 725-732.	1.2	10
692	Pathomics in urology. <i>Current Opinion in Urology</i> , 2020, 30, 823-831.	0.9	10
693	Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. <i>BJU International</i> , 2021, 128, 79-87.	1.3	10
694	Volume outcome relationship in penile cancer: a systematic review. <i>Current Opinion in Urology</i> , 2020, 30, 696-700.	0.9	10
695	Association of De Ritis ratio with oncological outcomes in patients with non-muscle invasive bladder cancer (NMIBC). <i>World Journal of Urology</i> , 2020, 39, 1961-1968.	1.2	10
696	Safety and Short-Term Oncological Outcomes of Thulium Fiber Laser En Bloc Resection of Non-Muscle-Invasive Bladder Cancer: A Prospective Non-Randomized Phase II Trial. <i>Bladder Cancer</i> , 2020, 6, 201-210.	0.2	10
697	Ureteral and urethral recurrence after radical cystectomy: a systematic review. <i>Current Opinion in Urology</i> , 2020, 30, 441-448.	0.9	10
698	Histologic Subtype, Tumor Grade, Tumor Size, and Race Can Accurately Predict the Probability of Synchronous Metastases in T2 Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e610-e618.	0.9	10
699	Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. <i>BJU International</i> , 2021, 127, 528-537.	1.3	10
700	The effect of sex on disease stage and survival after radical cystectomy: a population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 236.e1-236.e7.	0.8	10
701	Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI) – do we still need contrast media?. <i>European Radiology</i> , 2021, 31, 3754-3764.	2.3	10
702	Bladder cancer stage and mortality: urban vs. rural residency. <i>Cancer Causes and Control</i> , 2021, 32, 139-145.	0.8	10

#	ARTICLE	IF	CITATIONS
703	Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 180-190.	0.8	10
704	Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Nonâ€clear Cell Renal Cell Carcinoma Patients. <i>European Urology Focus</i> , 2021, 7, 598-607.	1.6	10
705	Accuracy and Clinical Utility of a Tumor Grade- and Stage-based Predictive Model in Localized Upper Tract Urothelial Carcinoma. <i>European Urology Focus</i> , 2022, 8, 761-768.	1.6	10
706	Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy. <i>World Journal of Urology</i> , 2021, 39, 3771-3779.	1.2	10
707	Deep Learning-based Recalibration of the CUETO and EORTC Prediction Tools for Recurrence and Progression of Nonâ€muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2022, 5, 109-112.	2.6	10
708	Survival of contemporary patients with non-metastatic urachal vs. non-urachal adenocarcinoma of the urinary bladder. <i>World Journal of Urology</i> , 2020, 38, 2819-2826.	1.2	10
709	Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies. <i>Molecular Cancer</i> , 2022, 21, 7.	7.9	10
710	Reassessment of the Efficacy of Carboplatin for Metastatic Urothelial Carcinoma in the Era of Immunotherapy: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 1687-1695.	1.6	10
711	Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis. <i>Immunotherapy</i> , 2022, 14, 709-725.	1.0	10
712	Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicity. <i>International Urology and Nephrology</i> , 2022, 54, 1521-1527.	0.6	10
713	Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in highâ€grade non-muscle-invasive urothelial bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 491.e11-491.e19.	0.8	10
714	Herbal/Hormonal Dietary Supplement Possibly Associated with Prostate Cancer Progression. <i>Clinical Cancer Research</i> , 2008, 14, 607-611.	3.2	9
715	Prospective Questionnaire-Based Evaluation of the Prevalence of Urinary Incontinence in Women with Chronic Cough. <i>Urologia Internationalis</i> , 2009, 83, 181-186.	0.6	9
716	Nomogram aids clinical decision making after radical cystectomy. <i>Nature Reviews Urology</i> , 2010, 7, 182-184.	1.9	9
717	Retroperitoneal Laparoscopic Kidney Biopsy: Technical Tips for a Minimally Invasive Approach. <i>Journal of Endourology</i> , 2011, 25, 1639-1642.	1.1	9
718	Novel Biomarkers to Predict Response and Prognosis in Localized Bladder Cancer. <i>Urologic Clinics of North America</i> , 2015, 42, 225-233.	0.8	9
719	TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2015, 33, 1965-1972.	1.2	9
720	The Effect of Obesity on Perioperative Outcomes Following Percutaneous Nephrolithotomy. <i>Journal of Endourology</i> , 2016, 30, 864-870.	1.1	9

#	ARTICLE	IF	CITATIONS
721	Impact of Intra- and Postoperative Blood Transfusion on the Incidence, Timing, and Pattern of Disease Recurrence After Radical Cystectomy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e681-e688.	0.9	9
722	Frequency and prognostic significance of incidental prostate cancer at radical cystectomy: Results from an international retrospective study. <i>European Journal of Surgical Oncology</i> , 2017, 43, 2193-2199.	0.5	9
723	Intermediate and long-term complications associated with adjuvant chemotherapy for stage I germ cell tumor patients. <i>Current Opinion in Urology</i> , 2018, 28, 485-490.	0.9	9
724	Adherence to guideline recommendations for lymph node dissection in squamous cell carcinoma of the penis: Effect on survival and complication rates. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 578.e11-578.e19.	0.8	9
725	Comparison of Open Versus Robotically Assisted Cytoreductive Radical Prostatectomy for Metastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e939-e945.	0.9	9
726	Radical Cystectomy in Pathological T4a and T4b Bladder Cancer Patients: Is There Any Space for Sub Stratification?. <i>Urologia Internationalis</i> , 2019, 102, 269-276.	0.6	9
727	Focal Neuroendocrine Differentiation of Conventional Prostate Adenocarcinoma as a Prognostic Factor after Radical Prostatectomy: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1374.	1.8	9
728	Contemporary trends of pelvic lymph node dissection at radical cystectomy for urothelial carcinoma of urinary bladder and associated cancer specific mortality and complications: comparison between octogenarian versus younger patients. <i>Cancer Epidemiology</i> , 2019, 59, 135-142.	0.8	9
729	Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. <i>World Journal of Urology</i> , 2019, 37, 2419-2427.	1.2	9
730	The effect of androgen deprivation treatment on subsequent risk of bladder cancer diagnosis in male patients treated for prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 1127-1135.	1.2	9
731	Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer. <i>World Journal of Urology</i> , 2020, 38, 2501-2511.	1.2	9
732	Inflammatory bowel disease and prostate cancer risk: A systematic review. <i>Arab Journal of Urology Arab Association of Urology</i> , 2020, 18, 207-212.	0.7	9
733	Contemporary Cytoreductive Nephrectomy Provides Survival Benefit in Clear-cell Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e730-e738.	0.9	9
734	An update on systemic therapy for penile cancer. <i>Current Opinion in Urology</i> , 2020, 30, 229-233.	0.9	9
735	The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages. <i>Cancer Causes and Control</i> , 2020, 31, 283-290.	0.8	9
736	Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities. <i>Cancer Causes and Control</i> , 2020, 31, 263-272.	0.8	9
737	Intravesical therapy for bladder cancer in the pandemic of Covid-19. <i>World Journal of Urology</i> , 2021, 39, 1313-1314.	1.2	9
738	Primary Ta high grade bladder tumors: Determination of the risk of progression. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 132.e7-132.e11.	0.8	9

#	ARTICLE	IF	CITATIONS
739	Impact of Adjuvant Chemotherapy on Survival of Patients with Advanced Residual Disease at Radical Cystectomy following Neoadjuvant Chemotherapy: Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 651.	1.0	9
740	Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 3337-3344.	1.2	9
741	Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis. <i>Current Opinion in Urology</i> , 2021, 31, 332-339.	0.9	9
742	Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review. <i>World Journal of Urology</i> , 2021, 39, 4085-4099.	1.2	9
743	Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities. <i>World Journal of Urology</i> , 2021, 39, 3781-3787.	1.2	9
744	Radical Cystectomy vs. Multimodality Treatment in T2NOMO Bladder Cancer: A Population-based, Age-matched Analysis. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e264-e271.	0.9	9
745	The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy. <i>World Journal of Urology</i> , 2022, 40, 103-110.	1.2	9
746	Metastasis-directed therapy and prostate-targeted therapy in oligometastatic prostate cancer: a systematic review. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 531-542.	3.9	9
747	Current Advances in Immune Checkpoint Inhibition and Clinical Genomics in Upper Tract Urothelial Carcinoma: State of the Art. <i>Current Oncology</i> , 2022, 29, 687-697.	0.9	9
748	Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration. <i>World Journal of Urology</i> , 2022, 40, 1167-1174.	1.2	9
749	Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 47.e1-47.e8.	0.8	8
750	Histopathology and prognosis of de novo bladder tumors following solid organ transplantation. <i>World Journal of Urology</i> , 2015, 33, 2087-2093.	1.2	8
751	Liquid biopsies in bladder cancer: did we find the Holy Grail for biomarker analyses?. <i>Translational Andrology and Urology</i> , 2016, 5, 980-983.	0.6	8
752	Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study. <i>Bladder Cancer</i> , 2016, 2, 91-99.	0.2	8
753	Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1189-1199.	1.5	8
754	Characterization of Late Recurrence After Radical Cystectomy in a Large Multicenter Cohort of Bladder Cancer Patients. <i>Urology</i> , 2017, 106, 119-124.	0.5	8
755	Impact of Prostate Involvement on Outcomes in Patients Treated with Radical Cystoprostatectomy for Bladder Cancer. <i>Urologia Internationalis</i> , 2017, 98, 290-297.	0.6	8
756	The surgical management of patients with clinical stage T4 bladder cancer: A single institution experience. <i>European Journal of Surgical Oncology</i> , 2017, 43, 808-814.	0.5	8

#	ARTICLE	IF	CITATIONS
757	Indication for a Single Postoperative Instillation of Chemotherapy in Non-muscle-invasive Bladder Cancer: What Factors Should Be Considered?. <i>European Urology Focus</i> , 2018, 4, 525-528.	1.6	8
758	The Effect of Institution Teaching Status on Perioperative Outcomes After Robotic Partial or Radical Nephrectomy. <i>Journal of Endourology</i> , 2018, 32, 621-629.	1.1	8
759	Contemporary Assessment of Long-Term Survival Rates in Patients With Stage I Nonseminoma Germ-Cell Tumor of the Testis: Population-Based Comparison Between Surveillance and Active Treatment After Initial Orchiectomy. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e1153-e1162.	0.9	8
760	Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 179.e1-179.e7.	0.8	8
761	Contemporary North-American population-based validation of the International Germ Cell Consensus Classification for metastatic germ cell tumors of the testis. <i>World Journal of Urology</i> , 2020, 38, 1535-1544.	1.2	8
762	Micropapillary Versus Urothelial Carcinoma of the Urinary Bladder: Stage at Presentation and Efficacy of Chemotherapy Across All Stages—A SEER-based Study. <i>European Urology Focus</i> , 2021, 7, 1332-1338.	1.6	8
763	Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1881-1891.	1.0	8
764	The clinical pharmacology of the medical treatment for overactive bladder in adults. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 707-720.	1.3	8
765	Differences in short-term outcomes between open versus robot-assisted radical cystectomy in frail malnourished patients. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1347-1352.	0.5	8
766	Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 235.e5-235.e14.	0.8	8
767	The microbiome in urinary tract infections in children—an update. <i>Current Opinion in Urology</i> , 2021, 31, 147-154.	0.9	8
768	Race/Ethnicity Determines Life Expectancy in Surgically Treated T1aNOMO Renal Cell Carcinoma Patients. <i>European Urology Focus</i> , 2022, 8, 191-199.	1.6	8
769	Differential Prognosis and Response of De novo vs. Secondary Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 2496.	1.7	8
770	Health-related quality of life in bladder cancer patients: general and cancer-specific instruments. Part 1. <i>Current Opinion in Urology</i> , 2021, 31, 297-303.	0.9	8
771	Quality indicators for the management of high-risk upper tract urothelial carcinoma requiring radical nephroureterectomy. <i>Current Opinion in Urology</i> , 2021, 31, 291-296.	0.9	8
772	Accuracy of Frozen Section Analysis of Urethral and Ureteral Margins During Radical Cystectomy for Bladder Cancer: A Systematic Review and Diagnostic Meta-Analysis. <i>European Urology Focus</i> , 2022, 8, 752-760.	1.6	8
773	Effects of Delayed Radical Prostatectomy and Active Surveillance on Localised Prostate Cancer—A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 3274.	1.7	8
774	Salvage Radical Prostatectomy: Baseline Prostate Cancer Characteristics and Survival Across SEER Registries. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e255-e263.	0.9	8

#	ARTICLE	IF	CITATIONS
775	Partial nephrectomy in frail patients: Benefits of robot-assisted surgery. <i>Surgical Oncology</i> , 2021, 38, 101588.	0.8	8
776	Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients. <i>Prostate</i> , 2021, 81, 1374-1381.	1.2	8
777	Regional differences in patient age and prostate cancer characteristics and rates of treatment modalities in favorable and unfavorable intermediate risk prostate cancer across United States SEER registries. <i>Cancer Epidemiology</i> , 2021, 74, 101994.	0.8	8
778	Comparison Between Urothelial and Non-Urothelial Urethral Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 629692.	1.3	8
779	Trends and Social Barriers for Inpatient Palliative Care in Patients With Metastatic Bladder Cancer Receiving Critical Care Therapies. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1344-1352.	2.3	8
780	Prostate Cancer Grade and Stage Misclassification in Active Surveillance Candidates: Black Versus White Patients. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1492-1499.	2.3	8
781	Survival benefit of chemotherapy in a contemporary cohort of metastatic urachal carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 165.e9-165.e15.	0.8	8
782	Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	1.3	8
783	Impact of the preoperative modified glasgow prognostic score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. <i>Minerva Urology and Nephrology</i> , 2021, , .	1.3	8
784	Plasmacytoid variant urothelial carcinoma of the bladder: effect of radical cystectomy and chemotherapy in non-metastatic and metastatic patients. <i>World Journal of Urology</i> , 2022, 40, 1481-1488.	1.2	8
785	The impact of lymphovascular invasion in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma: An extensive updated systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 243-261.	0.8	8
786	Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 273.e11-273.e20.	0.8	8
787	Lower urinary tract symptoms are associated with clinically relevant depression, anxiety, and stress symptoms. <i>Aging Male</i> , 2022, 25, 62-66.	0.9	8
788	Suboptimal use of pelvic lymph node dissection: Differences in guideline adherence between robot-assisted and open radical prostatectomy. <i>Canadian Urological Association Journal</i> , 2016, 10, 269.	0.3	7
789	Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different?. <i>World Journal of Urology</i> , 2016, 34, 105-112.	1.2	7
790	Preoperative anemia is associated with disease recurrence and progression in patients with non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 113.e9-113.e14.	0.8	7
791	Focal therapy of prostate cancer. <i>Current Opinion in Urology</i> , 2018, 28, 550-554.	0.9	7
792	Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer. <i>BJU International</i> , 2018, 122, 695-704.	1.3	7

#	ARTICLE	IF	CITATIONS
793	Surgically Treated Retroperitoneal Sarcoma: A Population-based Competing Risks Analysis. <i>European Urology Oncology</i> , 2018, 1, 346-351.	2.6	7
794	Six essential conditions for bladder-sparing strategies in bacillus Calmette-Guérin unresponsive bladder cancer. <i>Immunotherapy</i> , 2019, 11, 1083-1086.	1.0	7
795	Survival Effect of Chemotherapy in Metastatic Upper Urinary Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e97-e103.	0.9	7
796	Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer. <i>European Urology Focus</i> , 2021, 7, 1067-1074.	1.6	7
797	The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group. <i>Surgical Oncology</i> , 2020, 34, 312-317.	0.8	7
798	The significance of De Ritis ratio in patients with radiation-recurrent prostate cancer undergoing salvage radical prostatectomy. <i>Arab Journal of Urology Arab Association of Urology</i> , 2020, 18, 213-218.	0.7	7
799	Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent. <i>World Journal of Urology</i> , 2021, 39, 1947-1953.	1.2	7
800	Synchronous Metastasis Rates in T1 Renal Cell Carcinoma: A Surveillance, Epidemiology, and End Results Database-based Study. <i>European Urology Focus</i> , 2021, 7, 818-826.	1.6	7
801	The Cancer of the Bladder Risk Assessment (COBRA) score for estimating cancer-specific survival after radical cystectomy: external validation in a large multi-institutional cohort. <i>BJU International</i> , 2020, 126, 704-714.	1.3	7
802	Histomorphological analysis of false positive PI-RADS 4 and 5 lesions. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 636.e7-636.e12.	0.8	7
803	Role and efficacy of current biomarkers in bladder cancer. <i>AME Medical Journal</i> , 0, 5, 6-6.	0.4	7
804	Radical cystectomy improves survival in patients with stage T1 squamous cell carcinoma and neuroendocrine carcinoma of the urinary bladder. <i>European Journal of Surgical Oncology</i> , 2021, 47, 463-469.	0.5	7
805	Obesity is associated with adverse short-term perioperative outcomes in patients treated with open and robot-assisted radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 75.e17-75.e25.	0.8	7
806	The value and limitations of urothelial bladder carcinoma molecular classifications to predict oncological outcomes and cancer treatment response: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 15-33.	0.8	7
807	Functional Outcomes after Local Salvage Therapies for Radiation-Recurrent Prostate Cancer Patients: A Systematic Review. <i>Cancers</i> , 2021, 13, 244.	1.7	7
808	What is next in second- and later-line treatment of metastatic renal cell carcinoma? review of the recent literature. <i>Current Opinion in Urology</i> , 2021, 31, 276-284.	0.9	7
809	Sex-Related Differences Include Stage, Histology, and Survival in Urethral Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 135-143.	0.9	7
810	Acute kidney injury in COVID-19: are kidneys the target or just collateral damage? A comprehensive assessment of viral RNA and AKI rate in patients with COVID-19. <i>Current Opinion in Urology</i> , 2021, 31, 363-368.	0.9	7

#	ARTICLE	IF	CITATIONS
811	The prognostic value of sarcopenia in patients with prostate cancer: a systematic review. <i>Current Opinion in Urology</i> , 2021, 31, 315-323.	0.9	7
812	Differential prognostic impact of different Gleason patterns in grade group 4 in radical prostatectomy specimens. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1172-1178.	0.5	7
813	Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 806-815.	0.8	7
814	Prognostic blood-based biomarkers in patients treated with neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 471-479.	0.8	7
815	External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients. <i>International Journal of Urology</i> , 2022, 29, 17-24.	0.5	7
816	Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis. <i>Current Opinion in Urology</i> , 2022, 32, 61-68.	0.9	7
817	Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 778858.	1.3	7
818	Sex- and Age-Related Differences in the Distribution of Metastases in Patients With Upper Urinary Tract Urothelial Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 534-540.	2.3	7
819	Survival after radical prostatectomy versus radiation therapy in clinical node-positive prostate cancer. <i>Prostate</i> , 2022, 82, 740-750.	1.2	7
820	Effect of Neoadjuvant Chemotherapy on Complications, in-Hospital Mortality, Length of Stay and Total Hospital Costs in Bladder Cancer Patients Undergoing Radical Cystectomy. <i>Cancers</i> , 2022, 14, 1222.	1.7	7
821	Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology Young Academic Urologists: Urothelial Carcinoma Working Group. <i>European Urology Focus</i> , 2022, 8, 1635-1642.	1.6	7
822	Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study. <i>European Urology Open Science</i> , 2022, 39, 14-21.	0.2	7
823	Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 187-198.	2.0	7
824	Survival trends in chemotherapy exposed metastatic bladder cancer patients and chemotherapy effect across different age, sex, and race/ethnicity. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 380.e19-380.e27.	0.8	7
825	Outcomes of robotic-assisted versus open radical cystectomy in a large-scale, contemporary cohort of bladder cancer patients. <i>Journal of Surgical Oncology</i> , 2022, 126, 830-837.	0.8	7
826	Prognostic Model for Predicting Survival in Patients with Disease Recurrence Following Radical Cystectomy. <i>European Urology Focus</i> , 2015, 1, 75-81.	1.6	6
827	Risk stratification for kidney sparing procedure in upper tract urothelial carcinoma. <i>Translational Andrology and Urology</i> , 2016, 5, 711-719.	0.6	6
828	Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 89.e1-89.e5.	0.8	6

#	ARTICLE	IF	CITATIONS
829	Clinical value of cholinesterase in the prediction of biochemical recurrence after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 528.e7-528.e13.	0.8	6
830	Tissue biomarkers in nonmuscle-invasive bladder cancer. <i>Current Opinion in Urology</i> , 2018, 28, 584-590.	0.9	6
831	The effect of radical cystectomy on survival in patients with metastatic urothelial carcinoma of the urinary bladder. <i>Journal of Surgical Oncology</i> , 2019, 120, 1266-1275.	0.8	6
832	Contemporary use and survival after perioperative systemic chemotherapy in patients with locally advanced non-metastatic urothelial carcinoma of the bladder treated with radical cystectomy. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1253-1259.	0.5	6
833	Evaluation of Cause of Death After Radical Cystectomy for Patients With Bladder Cancer: The Impact of Age at the Time of Surgery. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e541-e548.	0.9	6
834	PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 496-505.	0.8	6
835	Survival After Partial Cystectomy for Variant Histology Bladder Cancer Compared With Urothelial Carcinoma: A Population-based Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 117-128.e5.	0.9	6
836	Impact of hospital and surgeon volumes on short-term and long-term outcomes of radical cystectomy. <i>Current Opinion in Urology</i> , 2020, Publish Ahead of Print, 701-710.	0.9	6
837	Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2020, 39, 2567-2577.	1.2	6
838	Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer – examining the utility of classifying Ta bladder cancer based on size. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 851.e19-851.e25.	0.8	6
839	Association of Processed Meats and Alcohol Consumption with Renal Cell Carcinoma: A Worldwide Population-Based Study. <i>Nutrition and Cancer</i> , 2021, 73, 2665-2670.	0.9	6
840	Nocebo Response in the Pharmacological Management of Overactive Bladder: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2021, 7, 1143-1156.	1.6	6
841	Bladder sparing landscape for bacillus Calmette-Guérin unresponsive bladder cancer. <i>Current Opinion in Urology</i> , 2020, 30, 542-546.	0.9	6
842	Contemporary Rates and Predictors of Open Conversion During Minimally Invasive Radical Prostatectomy for Nonmetastatic Prostate Cancer. <i>Journal of Endourology</i> , 2020, 34, 600-607.	1.1	6
843	The prognostic impact of tumour NSD2 expression in advanced prostate cancer. <i>Biomarkers</i> , 2020, 25, 268-273.	0.9	6
844	Radical cystectomy plus chemotherapy in patients with pure squamous cell bladder carcinoma: a population-based study. <i>World Journal of Urology</i> , 2021, 39, 813-822.	1.2	6
845	Comparing oncological outcomes of laparoscopic vs open radical nephroureterectomy for the treatment of upper tract urothelial carcinoma: A propensity score-matched analysis. <i>Arab Journal of Urology Arab Association of Urology</i> , 2021, 19, 31-36.	0.7	6
846	Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors. <i>World Journal of Urology</i> , 2021, 39, 2977-2985.	1.2	6

#	ARTICLE	IF	CITATIONS
847	Higher Cancer Mortality in Rural Upper Urinary Tract Urothelial Carcinoma Patients. <i>Urologia Internationalis</i> , 2021, 105, 624-630.	0.6	6
848	Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 85-95.	2.0	6
849	The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 785.e11-785.e17.	0.8	6
850	A Systematic Review and Scoping Analysis of Smoking Cessation after a Urological Cancer Diagnosis. <i>Journal of Urology</i> , 2021, 205, 1275-1285.	0.2	6
851	Response and Toxicity to the Second Course of 3 Cycles of 177Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 2489.	1.7	6
852	Flexible fibre optic vs digital ureteroscopy and enhanced vs unenhanced imaging for diagnosis and treatment of upper tract urothelial carcinoma (UTUC): results from the Clinical Research Office of the Endourology Society (CROES)â€UTUC registry. <i>BJU International</i> , 2021, 128, 734-743.	1.3	6
853	The effect of race on stage at presentation and survival in upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 788.e7-788.e13.	0.8	6
854	The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials. <i>European Urology Oncology</i> , 2022, 5, 138-145.	2.6	6
855	COVID-19 pandemic impact on uro-oncological disease outcomes at an Italian tertiary referral center. <i>World Journal of Urology</i> , 2022, 40, 263-269.	1.2	6
856	Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. <i>Molecular Carcinogenesis</i> , 2022, 61, 5-18.	1.3	6
857	Update on systemic treatment of upper tract urothelial carcinoma: a narrative review of the literature. <i>Translational Andrology and Urology</i> , 2021, 10, 4051-4061.	0.6	6
858	A comparison of perioperative outcomes of laparoscopic versus open nephroureterectomy for upper tract urothelial carcinoma: a propensity score matching analysis. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	1.3	6
859	Small Renal Masses With Tumor Size 0 to 2 cm: A SEER-Based Study and Validation of NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1340-1347.	2.3	6
860	Prognostic value of preoperative albumin to globulin ratio in patients treated with salvage radical prostatectomy for radiation recurrent prostate cancer. <i>Minerva Urology and Nephrology</i> , 2021, 73, 610-615.	1.3	6
861	Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy. <i>European Urology Oncology</i> , 2022, 5, 120-124.	2.6	6
862	Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2022, 29, 5307-5316.	0.7	6
863	Influence of steep Trendelenburg position on postoperative complications: a systematic review and meta-analysis. <i>Journal of Robotic Surgery</i> , 2022, 16, 1233-1247.	1.0	6
864	Contemporary seminal vesicle invasion rates in NCCN highâ€risk prostate cancer patients. <i>Prostate</i> , 2022, 82, 1051-1059.	1.2	6

#	ARTICLE	IF	CITATIONS
865	A Rare Case of Primary Mantle Cell Lymphoma of the Prostate: Clinical Aspects and Open Problems. <i>Urologia</i> , 2013, 80, 247-250.	0.3	5
866	Novel Urinary Markers for Detection of Bladder Cancer—Are we Failing?. <i>Journal of Urology</i> , 2014, 191, 9-10.	0.2	5
867	DKK-1 in prostate cancer diagnosis and follow up. <i>BMC Clinical Pathology</i> , 2014, 14, 11.	1.8	5
868	Partial nephrectomy driven by cavitron ultrasonic surgical aspirator under zero ischemia: a pilot study. <i>World Journal of Urology</i> , 2015, 33, 2015-2021.	1.2	5
869	Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. <i>Journal of Urology</i> , 2017, 198, 1269-1277.	0.2	5
870	Androgen receptor expression is associated with adverse pathological features in ureteral but not in pelvicalyceal urothelial carcinomas of the upper urinary tract. <i>World Journal of Urology</i> , 2017, 35, 943-949.	1.2	5
871	Effect of Stage Migration on Bladder Cancer: A Slow but Steady Improvement in Long-Term Survival Rates After Radical Cystectomy in Previous 25 Years. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e223-e228.	0.9	5
872	Comprehensive analysis of in-hospital delirium after major surgical oncology procedures. <i>Canadian Urological Association Journal</i> , 2019, 14, E84-E93.	0.3	5
873	Re: Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Carcinoma (PURE-01): An Open-label, Single-arm, Phase II Study. <i>European Urology</i> , 2019, 75, 695-696.	0.9	5
874	Prognostic role of the urokinase plasminogen activator (uPA) system in patients with nonmuscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 774-783.	0.8	5
875	Contemporary Assessment of Survival Rates in Stage I Testicular Seminoma: A Population-Based Comparison Between Surveillance and Active Treatment After Orchiectomy. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e793-e801.	0.9	5
876	Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma. <i>World Journal of Urology</i> , 2019, 37, 1631-1637.	1.2	5
877	Impact of Age on Perioperative Outcomes at Radical Prostatectomy: A Population-Based Study. <i>European Urology Focus</i> , 2020, 6, 1213-1219.	1.6	5
878	Temporal trends and social barriers for inpatient palliative care delivery in metastatic prostate cancer patients receiving critical care therapies. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 260-268.	2.0	5
879	Survival of Contemporary Patients With Non-metastatic Small-cell Carcinoma of Urinary Bladder, According to Alternative Treatment Modalities. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e450-e456.	0.9	5
880	Bladder cancer incidence rates and trends in young adults aged 20-39 years. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 934.e11-934.e19.	0.8	5
881	Fibroblast growth factor receptors across urothelial carcinoma landscape. <i>Current Opinion in Urology</i> , 2020, 30, 557-565.	0.9	5
882	The role of taxane-based chemotherapy in the treatment of prostate cancer. <i>Current Opinion in Urology</i> , 2020, 30, 527-533.	0.9	5

#	ARTICLE	IF	CITATIONS
883	Rates of other-cause mortality after radical cystectomy are decreasing over timeâ€”A population-based analysis over two decades. <i>Journal of Surgical Oncology</i> , 2020, 121, 1329-1336.	0.8	5
884	Validation of Hyponatremia as a Prognostic Predictor in Multiregional Upper Tract Urothelial Carcinoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 1218.	1.0	5
885	Transurethral resection of bladder tumor and the need for re-transurethral resection of bladder tumor. <i>Current Opinion in Urology</i> , 2020, 30, 370-376.	0.9	5
886	The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumour and benign prostatic hyperplasia: a systematic review and meta-analysis. <i>BJU International</i> , 2021, 127, 143-152.	1.3	5
887	Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 315-324.	1.0	5
888	Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Translational Andrology and Urology</i> , 2021, 10, 609-619.	0.6	5
889	Comparison between 1973 and 2004/2016 WHO grading systems in patients with Ta urothelial carcinoma of urinary bladder. <i>Journal of Clinical Pathology</i> , 2021, , jclinpath-2021-207400.	1.0	5
890	Dual immune check point blockade or immune check point-tyrosine kinase inhibitor combination: as a first-line treatment in metastatic renal cell carcinoma?. <i>Current Opinion in Urology</i> , 2021, 31, 270-275.	0.9	5
891	Comparison between small renal masses 0-2 cm vs. 2.1-4 cm in size: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 239.e1-239.e7.	0.8	5
892	Novel transurethral resection technologies and training modalities in the management of nonmuscle invasive bladder cancer: a comprehensive review. <i>Current Opinion in Urology</i> , 2021, 31, 324-331.	0.9	5
893	Comparison between 1973 and 2004/2016 World Health Organization grading in upper tract urothelial carcinoma treated with radical nephroureterectomy. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1707-1713.	1.0	5
894	Contemporary analysis of the effect of marital status on survival in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 789.e9-789.e17.	0.8	5
895	Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy. <i>Journal of Urology</i> , 2021, 206, 1122-1131.	0.2	5
896	Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Current Oncology</i> , 2021, 28, 3692-3704.	0.9	5
897	Prognostic significance of perirenal fat invasion and tumor size in pT1 to pT3a renal cell carcinoma: Results of a comprehensive multicenter study of the CORONA projectâ€”Can we improve prognostic discrimination of patients with stage pT3a tumors?. <i>Journal of Clinical Oncology</i> , 2015, 33, 416-416.	0.8	5
898	ABO Blood Group and Rhesus Factor Are Not Associated with Outcomes After Radical Cystectomy for Non-metastatic Urothelial Carcinoma of the Bladder. , 2017, 37, 5747-5753.		5
899	Effect of Age on Cancer-specific Mortality in Patients With Urothelial Carcinoma of the Urinary Bladder. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 880-888.	0.6	5
900	Immuno-oncology therapy in metastatic bladder cancer: A systematic review and network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103534.	2.0	5

#	ARTICLE	IF	CITATIONS
901	Evaluation of the Predictive Role of Blood-Based Biomarkers in the Context of Suspicious Prostate MRI in Patients Undergoing Prostate Biopsy. <i>Journal of Personalized Medicine</i> , 2021, 11, 1231.	1.1	5
902	MRI as a screening tool for prostate cancer: current evidence and future challenges. <i>World Journal of Urology</i> , 2023, 41, 921-928.	1.2	5
903	Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: A multicenter cohort from the European Association of Urology " Young Academic Urologists. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 195.e27-195.e35.	0.8	5
904	The placebo and nocebo effects in functional urology. <i>Nature Reviews Urology</i> , 2022, 19, 171-189.	1.9	5
905	Bladder-preserving strategies for Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected?. <i>Current Opinion in Urology</i> , 2020, 30, 584-593.	0.9	5
906	Re: Global Effects of Smoking, of Quitting, and of Taxing Tobacco. <i>European Urology</i> , 2014, 66, 176-178.	0.9	4
907	Prostate Cancer Risk Estimation Tool Use by Members of the American Urological Association: A Survey Based Study. <i>Journal of Urology</i> , 2015, 193, 1933-1937.	0.2	4
908	Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. <i>World Journal of Urology</i> , 2016, 34, 1155-1161.	1.2	4
909	Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 356-362.	0.8	4
910	Predicting local failure after radical cystectomy in patients with bladder cancer: Implications for the selection of candidates at adjuvant radiation therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 672.e1-672.e6.	0.8	4
911	Use of adjuvant chemotherapy in radical cystectomy patients aged >65 years: a population-based study from the surveillance epidemiology and end results (SEER)-medicare database. <i>Minerva Urology and Nephrology</i> , 2017, 69, 173-180.	1.3	4
912	Oncologic Effect of Cumulative Smoking Exposure in Patients Treated With Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e619-e627.	0.9	4
913	How to assess and improve health-related quality of life in bladder cancer patients. <i>Translational Andrology and Urology</i> , 2018, 7, S77-S80.	0.6	4
914	Molecularly-driven precision medicine for advanced bladder cancer. <i>World Journal of Urology</i> , 2018, 36, 1749-1757.	1.2	4
915	Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 343.e1-343.e8.	0.8	4
916	Urinary expression of genes involved in DNA methylation and histone modification for diagnosis of bladder cancer in patients with asymptomatic microscopic haematuria. <i>Oncology Letters</i> , 2019, 18, 57-62.	0.8	4
917	Risk stratification of upper tract urothelial carcinoma: A Review of the Current Literature. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 503-513.	1.1	4
918	Transfer of Knowledge in Urology: A Case Study of Jacob Eduard Polak (1818-1891) and the Introduction of Contemporary Techniques of Lithotomy and Lithotripsy from Vienna to Persia in the Mid-19th Century: A New Analysis of Scientific Papers from the 19th Century. <i>Urologia Internationalis</i> , 2019, 102, 1-12.	0.6	4

#	ARTICLE	IF	CITATIONS
919	Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract. <i>World Journal of Urology</i> , 2019, 37, 1329-1337.	1.2	4
920	Risk stratification for upper tract urinary carcinoma. <i>Translational Andrology and Urology</i> , 2020, 9, 1799-1808.	0.6	4
921	Association of Prostate Cancer with Nuts, Seeds, Alcohol and Processed Meats: A Worldwide Population-Based Study. <i>Nutrition and Cancer</i> , 2021, 73, 2538-2545.	0.9	4
922	Effect of stage and grade migration on cancer specific mortality in renal cell carcinoma patients, according to clear cell vs. non-clear cell histology: A contemporary population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 506-514.	0.8	4
923	Medical practice and placebo response: an inseparable bond?. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 228-231.	1.0	4
924	Comparative effectiveness of radical cystectomy and radiotherapy without chemotherapy in frail patients with bladder cancer. <i>Scandinavian Journal of Urology</i> , 2020, 54, 52-57.	0.6	4
925	The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 423-432.	0.8	4
926	Contemporary rates and predictors of open conversion during minimally invasive partial nephrectomy for kidney cancer. <i>Surgical Oncology</i> , 2021, 36, 131-137.	0.8	4
927	The effect of race/ethnicity on histological subtype distribution, stage at presentation and cancer specific survival in urethral cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 369.e9-369.e17.	0.8	4
928	OUP accepted manuscript. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1149-1157.	0.6	4
929	A systematic review and meta-analysis of prognostic impact of different Gleason patterns in ISUP grade group 4. <i>Minerva Urology and Nephrology</i> , 2021, 73, 42-49.	1.3	4
930	Trimodal therapy with high-dose-rate brachytherapy and hypofractionated external beam radiation combined with long-term androgen deprivation for unfavorable-risk prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 976-985.	1.0	4
931	The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer. <i>Prostate</i> , 2021, 81, 765-771.	1.2	4
932	Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. <i>European Urology Oncology</i> , 2022, 5, 285-295.	2.6	4
933	Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer. <i>European Urology Open Science</i> , 2021, 30, 63-66.	0.2	4
934	Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 4345-4354.	1.2	4
935	Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinoma. <i>Cancer Causes and Control</i> , 2022, 33, 25-35.	0.8	4
936	The impact of sex and age on distribution of metastases in patients with renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2021, 26, 962-970.	1.0	4

#	ARTICLE	IF	CITATIONS
937	Biomarkers for the prediction of oncologic outcomes in non-muscle invasive bladder cancer: state of affairs and new frontiers. <i>Translational Andrology and Urology</i> , 2018, 7, S753-S755.	0.6	4
938	Seasonal Variations in the Diagnosis of Testicular Germ Cell Tumors: A National Cancer Registry Study in Austria. <i>Cancers</i> , 2021, 13, 5377.	1.7	4
939	Urological adverse drug reactions of psychotropic medication in psychiatric inpatients – A drug surveillance report from German-speaking countries. <i>Journal of Psychiatric Research</i> , 2021, 144, 412-420.	1.5	4
940	Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach. <i>World Journal of Urology</i> , 2022, 40, 747-754.	1.2	4
941	A comparison of perioperative outcomes of laparoscopic versus open nephroureterectomy for upper tract urothelial carcinoma: a propensity score matching analysis. <i>Minerva Urology and Nephrology</i> , 2021, , .	1.3	4
942	Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicenter study. <i>Minerva Urology and Nephrology</i> , 2022, 73, .	1.3	4
943	Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups. <i>Prostate</i> , 2022, 82, 676-686.	1.2	4
944	Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates. <i>Prostate</i> , 2022, , .	1.2	4
945	Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma. <i>European Urology Focus</i> , 2022, 8, 1683-1686.	1.6	4
946	T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non-muscle-invasive Bladder Cancer Spectrum. <i>European Urology Focus</i> , 2022, , .	1.6	4
947	Molecular biomarkers to help select neoadjuvant systemic therapy for urothelial carcinoma of the bladder. <i>Current Opinion in Urology</i> , 0, Publish Ahead of Print, .	0.9	4
948	Bladder Tumors: Molecular Aspects and Clinical Management. <i>BJU International</i> , 2011, 108, E163-E163.	1.3	3
949	Non-Muscle-Invasive Bladder Cancer in the Elderly Patient. <i>Current Geriatrics Reports</i> , 2014, 3, 42-47.	1.1	3
950	Hyperthermia for non-muscle invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 313-321.	1.1	3
951	Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 238.e19-238.e27.	0.8	3
952	Retreatment after focal therapy for failure. <i>Current Opinion in Urology</i> , 2018, 28, 544-549.	0.9	3
953	Racial disparities in lymph node dissection at radical prostatectomy: A Surveillance, Epidemiology and End Results database analysis. <i>International Journal of Urology</i> , 2018, 25, 929-936.	0.5	3
954	Prevalence and Prognostic Value of the Polymorphic Variant 1245A>C of HSD3B1 in Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 389-394.	0.9	3

#	ARTICLE	IF	CITATIONS
955	Second line immune checkpoint inhibition in urothelial cancer. <i>Translational Andrology and Urology</i> , 2019, 8, 414-420.	0.6	3
956	4D perfusion CT of prostate cancer for image-guided radiotherapy planning: A proof of concept study. <i>PLoS ONE</i> , 2019, 14, e0225673.	1.1	3
957	Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails. <i>European Urology</i> , 2020, 77, 1-2.	0.9	3
958	Primary lymphomas of the genitourinary tract: A population-based study. <i>Asian Journal of Urology</i> , 2020, 7, 332-339.	0.5	3
959	Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 936.e7-936.e14.	0.8	3
960	The Effect of Systemic Chemotherapy on Survival in Patients With Localized, Regional, or Metastatic Adenocarcinoma of the Urinary Bladder. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 567-574.	0.6	3
961	The promise and challenges of neoadjuvant immunotherapy in the management of non-muscle-invasive bladder cancer. <i>BJU International</i> , 2020, 125, 753-755.	1.3	3
962	Ejaculation-sparing versus non-ejaculation-sparing anatomic GreenLight laser enucleo-vaporization of the prostate: first comparative study. <i>World Journal of Urology</i> , 2021, 39, 3455-3463.	1.2	3
963	Intravesical Therapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis of Disease Recurrence. <i>European Urology Focus</i> , 2022, 8, 447-456.	1.6	3
964	Surgical intervention in patients with urothelial carcinoma of the bladder and lymph node metastasis. <i>Current Opinion in Urology</i> , 2021, 31, 220-225.	0.9	3
965	Artificial intelligence in prostate histopathology: where are we in 2021?. <i>Current Opinion in Urology</i> , 2021, 31, 430-435.	0.9	3
966	Association between male infertility and prostate cancer: a systematic review and meta-analysis. <i>Current Opinion in Urology</i> , 2021, 31, 346-353.	0.9	3
967	Prognostic Impact of Different Gleason Patterns on Biopsy Within Grade Group 4 Prostate Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 9179-9187.	0.7	3
968	Prognostic value of the pre-operative serum albumin to globulin ratio in patients with non-metastatic prostate cancer undergoing radical prostatectomy. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1729-1735.	1.0	3
969	Alternating Cystoscopy with Bladder EpiCheck® in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model. <i>Bladder Cancer</i> , 2021, 7, 307-315.	0.2	3
970	Cancer Spectrum, Family History of Cancer and Overall Survival in Men with Germline BRCA1 or BRCA2 Mutations. <i>Journal of Personalized Medicine</i> , 2021, 11, 917.	1.1	3
971	Stage and cancer-specific mortality differ within specific Asian ethnic groups for upper tract urothelial carcinoma: North American population-based study. <i>International Journal of Urology</i> , 2021, 28, 1247-1252.	0.5	3
972	Bacillus Calmette-Guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction: Phase III KEYNOTE-676 study. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4591-TPS4591.	0.8	3

#	ARTICLE	IF	CITATIONS
973	Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS5590-TPS5590.	0.8	3
974	Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies. <i>World Journal of Urology</i> , 2021, , 1.	1.2	3
975	Racial differences in the distribution of bladder cancer metastases: a population-based analysis. <i>Central European Journal of Urology</i> , 2020, 73, 407-415.	0.2	3
976	Contemporary Trends and Efficacy of Pelvic Lymph Node Dissection at Radical Cystectomy for Urothelial and Variant Histology Carcinoma of the Urinary Bladder. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 195.e1-195.e8.	0.9	3
977	Response to Re: External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients. <i>International Journal of Urology</i> , 2022, 29, 96-96.	0.5	3
978	Treatment and Outcome of Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation: A Single-Center, Real-World Analysis of Retrospective Data. <i>Frontiers in Surgery</i> , 2021, 8, 763271.	0.6	3
979	Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 227-236.	0.9	3
980	The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. <i>European Urology Focus</i> , 2022, 8, 972-979.	1.6	3
981	Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer. <i>Prostate International</i> , 2022, 10, 21-27.	1.2	3
982	Comparison of short-term and long-term neoadjuvant hormone therapy prior to radical prostatectomy: a systematic review and meta-analysis. <i>Scandinavian Journal of Urology</i> , 2022, 56, 85-93.	0.6	3
983	Carboplatin-based adjuvant chemotherapy versus observation after radical cystectomy in patients with pN1-3 urothelial bladder cancer. <i>World Journal of Urology</i> , 2022, 40, 1489-1496.	1.2	3
984	Race/Ethnicity may be an Important Predictor of Life Expectancy in Localized Prostate Cancer Patients: Novel Analyses Using Social Security Administration Life Tables. <i>Journal of Racial and Ethnic Health Disparities</i> , 2023, 10, 708-717.	1.8	3
985	Nonâ€œorgan confined stage and upgrading rates in exclusive PSA highâ€œrisk prostate cancer patients. <i>Prostate</i> , 2022, 82, 687-694.	1.2	3
986	Prognostic impact of insulinâ€œlike growth factorâ€œ1 and its binding proteins, insulinâ€œlike growth factorâ€œ1 binding proteinâ€œ2 and â€œ3, on adverse histopathological features and survival outcomes after radical cystectomy. <i>International Journal of Urology</i> , 2022, , .	0.5	3
987	The Role of Prior Bladder Cancer on Recurrence in Patients Treated with Radical Nephroureterectomy. <i>Clinical Genitourinary Cancer</i> , 2021, , .	0.9	3
988	Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis. <i>World Journal of Urology</i> , 0, , .	1.2	3
989	Urethrectomy at the time of radical cystectomy for non-metastatic urothelial carcinoma of the bladder: a collaborative multicenter study. <i>World Journal of Urology</i> , 0, , .	1.2	3
990	Laparoscopic Management of Sacral Neurinoma Causing Hydronephrosis. <i>Urologia</i> , 2012, 79, 107-110.	0.3	2

#	ARTICLE	IF	CITATIONS
991	Potential role of photodynamic techniques combined with new generation flexible ureterorenoscopes and molecular markers for the management of urothelial carcinoma of the upper urinary tract: adapting new technologies for the diagnosis and management of upper tract urothelial carcinoma. <i>BJU International</i> , 2012, 109, 613-614.	1.3	2
992	Innovations in the Endoscopic Management of Bladder Cancer: Is the Era of White Light Cystoscopy Over?. <i>Urologia</i> , 2013, 80, 1-8.	0.3	2
993	Re: Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer. <i>European Urology</i> , 2014, 66, 386-387.	0.9	2
994	The role for surgery in high-risk prostate cancer. <i>Wiener Medizinische Wochenschrift</i> , 2015, 165, 395-400.	0.5	2
995	Reducing Complications After Surgery: Still a Long Way To Go. <i>European Urology Focus</i> , 2016, 2, 1-2.	1.6	2
996	Electronic Cigarettes: A Wolf in Sheep's Clothing. <i>European Urology</i> , 2017, 71, 924-925.	0.9	2
997	ICUD guidelines for upper tract urothelial carcinoma: a state-of-the-art evidence-based guidance for clinical decisions regarding diagnosis, management and treatment. <i>World Journal of Urology</i> , 2017, 35, 325-326.	1.2	2
998	Organ Preservation Is Less Frequently Performed in Women Surgically Treated for Papillary Renal Cell Carcinoma—Results of a Comprehensive Multicenter Study. <i>Urology</i> , 2017, 109, 107-114.	0.5	2
999	Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 35-44.e1.	0.9	2
1000	Impact of Sex on Response to Neoadjuvant Chemotherapy in Patients with Upper-tract Urothelial Cancer. <i>European Urology Open Science</i> , 2020, 19, 16-19.	0.2	2
1001	An up-to-date catalogue of urinary markers for the management of prostate cancer. <i>Current Opinion in Urology</i> , 2020, Publish Ahead of Print, 684-688.	0.9	2
1002	Regular Coffee Consumption Is Associated with Lower Regional Adiposity Measured by DXA among US Women. <i>Journal of Nutrition</i> , 2020, 150, 1909-1915.	1.3	2
1003	Metabolic Syndrome Predicts Worse Perioperative Outcomes in Patients Treated With Partial Nephrectomy for Renal Cell Carcinoma. <i>Urology</i> , 2020, 140, 91-97.	0.5	2
1004	A Plea for the Evaluation of the Carbon Footprint of New Mini-invasive Surgical Technologies in Urology. <i>European Urology</i> , 2020, 78, 474-476.	0.9	2
1005	Novel technologies that change the diagnostic and treatment paradigm in urology. <i>Current Opinion in Urology</i> , 2020, 30, 475-476.	0.9	2
1006	Frontiers in combining immune checkpoint inhibitors for advanced urothelial cancer management. <i>Current Opinion in Urology</i> , 2020, 30, 457-466.	0.9	2
1007	Intraoperative aerosol viral transmission in minimally invasive surgery: a scoping review and impact on clinical guidelines and practice during the onset of the coronavirus disease 2019 (COVID-19) pandemic. <i>BJU International</i> , 2021, 127, 349-360.	1.3	2
1008	Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy. <i>European Urology Oncology</i> , 2021, 4, 301-304.	2.6	2

#	ARTICLE	IF	CITATIONS
1009	Presence of biopsy Gleason pattern 5+3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patterns+. Prostate, 2021, 81, 778-784.	1.2	2
1010	Association of Negative Followup Biopsy and Reclassification during Active Surveillance of Prostate Cancer: A Systematic Review and Meta-Analysis. Journal of Urology, 2021, 205, 1559-1568.	0.2	2
1011	Metabolic syndrome predicts worse perioperative outcomes in patients treated with radical prostatectomy for non-metastatic prostate cancer. Surgical Oncology, 2021, 37, 101519.	0.8	2
1012	Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients. Prostate, 2021, 81, 1055-1063.	1.2	2
1013	Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile. Minerva Urology and Nephrology, 2022, 74, .	1.3	2
1014	The Consequences of Inadvertent Radical Nephrectomy in the Treatment of Upper Tract Urothelial Carcinoma. Urology, 2021, 154, 127-135.	0.5	2
1015	Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis. European Journal of Cancer, 2021, 155, 245-255.	1.3	2
1016	Adverse events of different chemotherapy regimens in the first-line treatment of patients with advanced or metastatic urothelial cancer: A systematic review and network meta-analysis of randomized controlled trials. Seminars in Oncology, 2021, 48, 181-192.	0.8	2
1017	Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients. Prostate, 2022, 82, 120-131.	1.2	2
1018	Bladder cancer risk: Use of PLCO and NLST to identify a suitable screening cohort.. Journal of Clinical Oncology, 2014, 32, 4546-4546.	0.8	2
1019	Integrative molecular profiling challenges robustness of prognostic signature scores in multifocal prostate cancer.. Journal of Clinical Oncology, 2018, 36, 96-96.	0.8	2
1020	The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 685.e17-685.e25.	0.8	2
1021	Survival after radical prostatectomy vs. radiation therapy in ductal carcinoma of the prostate. International Urology and Nephrology, 2022, 54, 89-95.	0.6	2
1022	Association of statins use and mortality outcomes in prostate cancer patients who received androgen deprivation therapy: a systematic review and meta-analysis. Central European Journal of Urology, 2021, 74, 484-490.	0.2	2
1023	Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer. Journal of Cancer Research and Clinical Oncology, 2022, 148, 3091-3102.	1.2	2
1024	Ischemic Priapism in a 12 Year Old Patient Associated With Coronavirus Disease 2019 (COVID-19): A Case Report. Urology, 2022, 165, 316-318.	0.5	2
1025	Radiation therapy compared to radical prostatectomy as first-line definitive therapy for patients with high-risk localised prostate cancer: An updated systematic review and meta-analysis. Arab Journal of Urology Arab Association of Urology, 2022, 20, 71-80.	0.7	2
1026	Quality indicators for the management of muscle-invasive bladder cancer in the perioperative setting of radical cystectomy: a narrative review. Translational Cancer Research, 2022, 11, 908-917.	0.4	2

#	ARTICLE	IF	CITATIONS
1027	Re: Phase II Study of Gemcitabine and Split-dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2022, , .	0.9	2
1028	Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level. <i>Prostate</i> , 2022, 82, 1210-1218.	1.2	2
1029	The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy. <i>European Urology Open Science</i> , 2022, 41, 74-80.	0.2	2
1030	Clinical and biological markers for risk-stratification of T1 high-grade non-muscle invasive bladder cancer. <i>Current Opinion in Urology</i> , 0, Publish Ahead of Print, .	0.9	2
1031	Optimal results come from optimal surgery and optimal (neoadjuvant) systemic therapy. <i>BJU International</i> , 2014, 113, 516-517.	1.3	1
1032	Incorporating biomarker research in a real-world setting: Challenges of a prophecy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 219-221.	0.8	1
1033	The Future of Prostate Cancer Diagnosis: Biomarkers, Biopsy, Both, or Neither?. <i>European Urology Focus</i> , 2015, 1, 97-98.	1.6	1
1034	There Are Cooler Ways to Die Than Smoking: Urologists of the World, Unite Against This Health Care Tragedy. <i>European Urology Focus</i> , 2015, 1, 1-2.	1.6	1
1035	Reply to Michael Froehner, Rainer Koch, Manfred P. Wirth's Letter to the Editor: Malte Rieken, Shahrokh F. Shariat, Luis A. Kluth, et al. Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. <i>Eur Urol</i> . In press. http://dx.doi.org/10.1016/j.eururo.2015.05.038 . <i>European Urology</i> , 2015, 68, e104-e105.	0.9	1
1036	Building bridges in urothelial carcinoma to face common challenges. <i>Translational Andrology and Urology</i> , 2016, 5, 745-748.	0.6	1
1037	Re: Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. <i>European Urology</i> , 2016, 70, 205-206.	0.9	1
1038	The effect of ABO and Rhesus blood grouping systems on oncological outcome in patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 671.e17-671.e23.	0.8	1
1039	Robot-assisted partial nephrectomy. <i>Current Opinion in Urology</i> , 2018, 28, 123-131.	0.9	1
1040	External Validation of the Pathologic Nodal Staging Score for Prostate Cancer: A Population-based Study. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e59-e65.	0.9	1
1041	PD41-10 ROBOTIC RADICAL CYSTECTOMY IS ASSOCIATED WITH SHORTER LENGTH OF STAY AND LESS BLOOD LOSS THAN OPEN RADICAL CYSTECTOMY: RESULTS FROM A LARGE MULTICENTER RETROSPECTIVE COHORT. <i>Journal of Urology</i> , 2018, 199, .	0.2	1
1042	Epidemiology and Sociocultural Differences for Bladder Cancer. , 2019, , 291-301.		1
1043	Nonmuscle invasive urothelial cancer: Bacillus Calmette-Guérin instillation or checkpoint inhibitor immunotherapy?. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 319-323.	0.3	1
1044	Neoadjuvant therapy in urothelial cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 329-333.	0.3	1

#	ARTICLE	IF	CITATIONS
1045	Reply to Nicholas G. Zaorsky, Daniel E. Spratt, and Pierre Blanchard's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. <i>Eur Urol</i> 2019;75:319-28. <i>European Urology</i> , 2019, 75, e98-e99.	0.9	1
1046	Drug strategies for bladder cancer in the elderly: is there promise for the future?. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1387-1396.	0.9	1
1047	Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy. <i>Canadian Urological Association Journal</i> , 2019, 14, E173-E179.	0.3	1
1048	Assessment of other-cause mortality in localized renal cell carcinoma patients within 15 years: A population-based analysis. <i>Journal of Surgical Oncology</i> , 2020, 122, 1506-1513.	0.8	1
1049	Prognostic models to help predict patient responses to intravesical immunotherapy. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 243-251.	0.4	1
1050	Adherence to guideline recommendations for multimodality treatment of patients with pT2-3 M0 non-urothelial carcinoma of the urinary bladder: Temporal trends and survival outcomes. <i>International Journal of Urology</i> , 2020, 27, 402-407.	0.5	1
1051	Clinical Impact and Statistical Significance of Multiparametric Magnetic Resonance Imaging for Local Staging of Prostate Cancer. <i>European Urology</i> , 2021, 79, 186-187.	0.9	1
1052	Prognostic factors in patients with small renal masses: a comparison between <2 vs. 2.1-4cm renal cell carcinomas. <i>Cancer Causes and Control</i> , 2021, 32, 119-126.	0.8	1
1053	Re: Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. <i>European Urology</i> , 2021, 79, 163-164.	0.9	1
1054	Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma. <i>Turkish Journal of Urology</i> , 2021, 47, S33-S44.	1.3	1
1055	Detection of Urothelial Bladder Cancer Based on Urine and Tissue Telomerase Activity Measured by Novel RT-TRAP-2PCR Method. <i>Journal of Clinical Medicine</i> , 2021, 10, 1055.	1.0	1
1056	Difference in Incontinence Pad Use between Patients after Radical Prostatectomy and Cancer-Free Population with Subgroup Analysis for Open vs. Minimally Invasive Radical Prostatectomy: A Descriptive Analysis of Insurance Claims-Based Data. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 6891.	1.2	1
1057	Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis. <i>Immunotherapy</i> , 2021, 13, 917-929.	1.0	1
1058	Pilot study on the correlation of multiphoton microscopy of human testicular tumors with histology.. <i>Journal of Clinical Oncology</i> , 2012, 30, 338-338.	0.8	1
1059	Frequent truncating mutations of the cohesin complex gene STAG2 in urothelial carcinoma of the bladder.. <i>Journal of Clinical Oncology</i> , 2014, 32, 290-290.	0.8	1
1060	MP32-10a-f COMPARATIVE EFFECTIVENESS OF ROBOTIC ASSISTED AND OPEN RADICAL CYSTECTOMY IN CONTEMPORARY COHORTS OF BLADDER CANCER PATIENTS: AN INTERNATIONAL MULTICENTER COLLABORATION. <i>Journal of Urology</i> , 2019, 201, .	0.2	1
1061	Expression Analysis and Mutational Status of Histone Methyltransferase KMT2D at Different Upper Tract Urothelial Carcinoma Locations. <i>Journal of Personalized Medicine</i> , 2021, 11, 1147.	1.1	1
1062	Cancer-specific mortality after radical prostatectomy vs external beam radiotherapy in high-risk Hispanic/Latino prostate cancer patients. <i>International Urology and Nephrology</i> , 2021, 54, 81.	0.6	1

#	ARTICLE	IF	CITATIONS
1063	Metastasis Within Three Years from Radical Nephroureterectomy as a Potential Surrogate for Overall Survival. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 389.e1-389.e7.	0.9	1
1064	Comparative effectiveness of moderate hypofractionation with volumetric modulated arc therapy versus conventional 3D-radiotherapy after radical prostatectomy. <i>Strahlentherapie Und Onkologie</i> , 2022, , 1.	1.0	1
1065	Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics. <i>Cancers</i> , 2022, 14, 1781.	1.7	1
1066	The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis. <i>International Journal of Surgical Pathology</i> , 2023, 31, 157-166.	0.4	1
1067	Results for patients with muscle-invasive bladder cancer (MIBC) in the CheckMate 274 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4585-4585.	0.8	1
1068	Evidence-based Urology. <i>BJU International</i> , 2011, 107, 1844-1844.	1.3	0
1069	Bladder cancer. <i>Current Opinion in Urology</i> , 2014, 24, 483-486.	0.9	0
1070	Re: Impact of Smoking Status on Bladder Tumor Recurrence after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2014, 191, 557-559.	0.2	0
1071	European Urology: Serving Our Readership Through Systematic Peer Review, Use of Reporting Standards, and Encouragement of Postpublication Review. <i>European Urology</i> , 2015, 67, 188-190.	0.9	0
1072	Re: Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT. <i>European Urology</i> , 2015, 68, 537-538.	0.9	0
1073	Reply to Marco Borghesi, Gaetano La Manna, and Riccardo Schiavina's Letter to the Editor re: Sabine D. Brookman-May, Matthias May, Ingmar Wolff, et al. Evaluation of the Prognostic Significance of Perirenal Fat Invasion and Tumor Size in Patients with pT1â€“pT3a Localized Renal Cell Carcinoma in a Comprehensive Multicenter Study of the CORONA Project. Can We Improve Prognostic Discrimination for Patients with Stage pT3a tumors? <i>Eur Urol</i> 2015;67:943â€“51. <i>European Urology</i> , 2016, 69, e101-e102.	0.9	0
1074	Re: Failure-Free Survival and Radiotherapy in Patients with Newly Diagnosed Nonmetastatic Prostate Cancer: Data from Patients in the Control Arm of the STAMPEDE Trial. <i>European Urology</i> , 2016, 70, 398-399.	0.9	0
1075	Adrenal Lesions: Progress on All Fronts. <i>European Urology Focus</i> , 2016, 1, 215-216.	1.6	0
1076	Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. <i>European Urology</i> , 2016, 69, 755-756.	0.9	0
1077	Re: Comparative Effectiveness of Treatment Strategies for Bladder Cancer with Clinical Evidence of Regional Lymph Node Involvement. <i>European Urology</i> , 2017, 72, 474-475.	0.9	0
1078	Re: Adjuvant Chemotherapy vs Observation for Patients with Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. <i>European Urology</i> , 2017, 72, 1025-1026.	0.9	0
1079	Hospitalization before surgery and subsequent risk of infective complications after radical cystectomy: A population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 659.e7-659.e12.	0.8	0
1080	Re: Radiation with or Without Antiandrogen Therapy in Recurrent Prostate Cancer. <i>European Urology</i> , 2017, 72, 471-472.	0.9	0

#	ARTICLE	IF	CITATIONS
1081	Re: Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. <i>European Urology</i> , 2018, 74, 680-681.	0.9	0
1082	Epidemiology and Sociocultural Differences for Bladder Cancer. , 2018, , 1-11.		0
1083	Re: Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. <i>European Urology</i> , 2019, 76, 408-409.	0.9	0
1084	Association of Hyponatremia With Survival in Patients With Castration-resistant Prostate Cancer: A Clinical Commentary. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e1188-e1192.	0.9	0
1085	Reply to Alba Fiorentino, Angelo Errico, and Marcello Scarcia's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. <i>Eur Urol</i> 2019;75:319-28. <i>European Urology</i> , 2019, 75, e95.	0.9	0
1086	Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer. <i>European Urology</i> , 2020, 77, 132-133.	0.9	0
1087	How to deal with steroids use in the management of metastatic prostate cancer during pandemic. <i>Translational Andrology and Urology</i> , 2020, 9, 1546-1549.	0.6	0
1088	Re: Cabazitaxel Versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. <i>European Urology</i> , 2020, 77, 758-759.	0.9	0
1089	Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [68Ga]Ga-PSMA ligand PET/CT(MRI). <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 439-447.	2.0	0
1090	Re: Enzalutamide and Survival in Nonmetastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2021, 79, 430-431.	0.9	0
1091	Reply to Johanna Noel, Olivier Huillard, and Francois Goldwasser's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2020.10.006 . Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?. <i>European Urology</i> , 2021, 79,	0.9	0
1092	Reply to Francesco Montorsi, Marco Bandini, and Andrea Necchi's Letter to the Editor re: Francesco Soria, Marco Moschini, David D'Andrea, et al. Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. <i>Eur Urol Focus</i> 2020;6:1233-9. <i>European Urology Focus</i> , 2021, ,	1.6	0
1093	Benefit of Adjuvant Chemotherapy After Radical Cystectomy for Treatment of Urothelial Carcinoma of the Bladder in the Elderly - An International Multicenter Study. <i>Bladder Cancer</i> , 2021, 7, 173-185.	0.2	0
1094	COVID-19 crisis and minimally invasive surgery: a narrative review on intraoperative aerosol viral transmission and their impact on guidelines and clinical practice in Austria. <i>Current Opinion in Urology</i> , 2021, 31, 340-345.	0.9	0
1095	ASO Author Reflections: Is There Any Difference Among Various Gleason Scores Classified as Grade Group 4 Prostate Cancer?. <i>Annals of Surgical Oncology</i> , 2021, 28, 9188-9189.	0.7	0
1096	Reply by Authors. <i>Journal of Urology</i> , 2021, 206, 79-79.	0.2	0
1097	Reply to Xiaoshuai Gao, Guo Chen, and Xin Wei's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>Eur Urol</i> 2021;79:783-92. <i>European Urology</i> , 2021, 80, e145-e146.	0.9	0
1098	Increased risk of postoperative in-hospital complications after radical prostatectomy in patients with prior organ transplant. <i>Prostate</i> , 2021, 81, 1294-1302.	1.2	0

#	ARTICLE	IF	CITATIONS
1099	Risk Stratification of Upper Tract Urothelial Carcinoma for Kidney-Sparing Surgery. , 2021, , 387-402.		0
1100	Combination of urinary fibrinogen β -chain and tyrosine-phosphorylated proteins for the detection of bladder cancer. Future Science OA, 2021, 7, FSO758.	0.9	0
1101	Correlation of Immunohistochemical Molecular Staging of Bladder Biopsies and Radical Cystectomy Specimens. Japanese Journal of Urology, 2001, 92, 256.	0.0	0
1102	Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma.. Journal of Clinical Oncology, 2012, 30, 281-281.	0.8	0
1103	Multi-institutional evaluation of the prognostic significance of altered mammalian target of rapamycin (mTOR) pathway biomarkers in upper-tract urothelial carcinoma (UTUC).. Journal of Clinical Oncology, 2014, 32, 323-323.	0.8	0
1104	Multi-institutional validation of the predictive value of Ki-67 in patients with high-grade urothelial carcinoma of the upper urinary tract.. Journal of Clinical Oncology, 2015, 33, 371-371.	0.8	0
1105	Individualized treatment schedule and investigator \hat{c} 's defined time to resistance (TTRi) may prolong survival in patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology, 2015, 33, e15585-e15585.	0.8	0
1106	Multi-institutional validation of the predictive value of Ki-67 in patients with high-grade urothelial carcinoma of the upper urinary tract.. Journal of Clinical Oncology, 2015, 33, 4569-4569.	0.8	0
1107	Predictive models for improved prognostication and selection of neoadjuvant and adjuvant systemic chemotherapy in upper tract urothelial cell carcinoma.. Journal of Clinical Oncology, 2016, 34, 456-456.	0.8	0
1108	Contemporary concepts and controversies in the diagnosis and management of urothelial carcinoma. Translational Andrology and Urology, 2016, 5, 633-635.	0.6	0
1109	The role of cytoreductive radical prostatectomy (cRP) in men with hormone-sensitive, metastatic prostate cancer (mPCA).. Journal of Clinical Oncology, 2017, 35, 241-241.	0.8	0
1110	Prognostic value of PD-1 and PD-L1 expression in patients with high-grade urothelial carcinoma of the upper urinary tract.. Journal of Clinical Oncology, 2017, 35, 358-358.	0.8	0
1111	Comprehensive molecular profiling of multi-focal prostate cancer and concomitant lymph node metastasis: Implications for tissue-based prognostic biomarkers.. Journal of Clinical Oncology, 2017, 35, 5061-5061.	0.8	0
1112	Prognostic impact of primary tumor location in advanced urothelial carcinoma: The EORTC series.. Journal of Clinical Oncology, 2017, 35, e16034-e16034.	0.8	0
1113	PD13-01 \hat{c} COMPARATIVE EFFECTIVENESS OF INTRAVESICAL BCG-TICE AND BCG-MOREAU IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER. Journal of Urology, 2019, 201, .	0.2	0
1114	MP22-10 \hat{c} WHICH POSITIVE SURGICAL MARGINS FEATURES IMPACT ON THE RISK OF PROSTATE CANCER SPECIFIC MORTALITY? A DISEASE-TAILORED, COMPETING-RISK, LONG-TERM ANALYSIS. Journal of Urology, 2019, 201, .	0.2	0
1115	PD13-08 \hat{c} STRATIFICATION OF INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS: IMPLICATIONS FOR ADJUVANT THERAPIES.. Journal of Urology, 2019, 201, .	0.2	0
1116	PD60-10 \hat{c} IMPACT OF PREOPERATIVE CONTROLLING NUTRITIONAL STATUS (CONUT) SCORE ON PERIOPERATIVE MORBIDITY AND SURVIVAL OUTCOMES IN PATIENTS WITH BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY: A MULTICENTER ANALYSIS. Journal of Urology, 2020, 203, .	0.2	0

#	ARTICLE	IF	CITATIONS
1117	PD51-09â€fTHE CANCER OF THE BLADDER RISK ASSESSMENT (COBRA) SCORE FOR ESTIMATING CANCER-SPECIFIC SURVIVAL AFTER RADICAL CYSTECTOMY. <i>Journal of Urology</i> , 2020, 203, e1086.	0.2	0
1118	PD60-05â€fNEOADJUVANT CHEMOTHERAPY PLUS RADICAL CYSTECTOMY VERSUS RADICAL CYSTECTOMY ALONE IN CLINICAL T2 BLADDER CANCER PATIENTS WITHOUT HYDRONEPHROSIS. <i>Journal of Urology</i> , 2020, 203, e1275.	0.2	0
1119	Exploring the molecular basis of sexual dimorphism in bladder cancer. <i>Nature Reviews Urology</i> , 2020, 17, 487-488.	1.9	0
1120	Atezolizumab (atezo) therapy for locally advanced/metastatic urinary tract carcinoma (mUTC) in patients (pts) with poor performance status (PS): Analysis of the prospective global SAUL study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5035-5035.	0.8	0
1121	Dissection of primary prostate cancer to determine the clonal origin of synchronous lymph node metastasis.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17614-e17614.	0.8	0
1122	MP82-06â€fNEW CLASSIFICATION FOR UPPER TRACT UROTHELIAL CARCINOMA TO ENHANCE RISK STRATIFICATION OF PATIENTS ELIGIBLE TO ENDOSCOPIC MANAGEMENT: AN INTERNATIONAL COLLABORATIVE STUDY. <i>Journal of Urology</i> , 2020, 203, .	0.2	0
1123	PD03-08â€fTHE NECESSITY OF A SECOND TRANSURETHRAL RESECTION FOR PATIENTS DIAGNOSED WITH PTAHG TUMOR AT FIRST TUR: A MULTICENTER COLLABORATION OF EAU YOUNG ACADEMIC UROLOGISTS UROTHELIAL CARCINOMA GROUP. <i>Journal of Urology</i> , 2020, 203, .	0.2	0
1124	Molecular characterization to delineate the clonal evolution of primary prostate cancer with synchronous lymph node metastasis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 266-266.	0.8	0
1125	Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancer. <i>World Journal of Urology</i> , 2022, , 1.	1.2	0
1126	Comment on: Postoperative outcomes of Fast-Track-enhanced recovery protocol in open radical cystectomy: comparison with standard management in a high-volume center and Trifecta proposal. <i>Minerva Urology and Nephrology</i> , 2022, 74, 119-121.	1.3	0
1127	ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	0
1128	ASO Visual Abstract: Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	0